Document:

Finished Product Supply Agreement dated October 8, 2003

 Exhibit 10.6 
 [ ** ] = PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. AN UNREDACTED VERSION OF THIS AGREEMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 FINISHED PRODUCT SUPPLY AGREEMENT 
 THIS FINISHED PRODUCT SUPPLY AGREEMENT (this “Agreement”) dated as of October 8, 2003, and effective as of the Closing Date (the
“Effective Date”) is made and entered into by and between Aventis Pharmaceuticals Inc., a company organized and existing under the laws of Delaware (“Aventis”), and Axcan Pharma Inc., a corporation organized and
existing under the laws of Canada (“Axcan Pharma”, on behalf of itself and its Affiliates, collectively, the “Purchaser”). Capitalized terms used in this Agreement shall have the meanings ascribed to them in Article
1 hereof or as otherwise set forth herein; capitalized terms used herein without definition shall have the meanings ascribed to them in the Product Acquisition Agreement (as defined below). 
 RECITALS 
 WHEREAS,
Aventis is engaged in the manufacture in finished product form of the compound sucralfate in tablet and suspension form as sold in the United States under the registered trademark Carafate®; 
 WHEREAS, pursuant to an Agreement dated April 1,1985, as amended (the “API Supply
Agreement”), by and between Aventis, as successor in interests to Marion Laboratories, Inc., and Chugai Pharmaceutical Co., Ltd., a corporation organized and existing under the laws of Japan (the “API Supplier”), the API
Supplier is engaged in supplying Aventis with aluminum sucrose octasulfate (the “Bulk Compound”) used in the manufacture of the Product; 
 WHEREAS, this Agreement is being entered into in connection with certain transactions in which certain Affiliates of Aventis are divesting and licensing certain assets related to the Products to certain Affiliates of
Purchaser pursuant to a Product Acquisition Agreement, as of the date hereof (the “Product Acquisition Agreement”); 
 WHEREAS, Purchaser desires to have Aventis manufacture and supply it with Products for sale and distribution in the Territory during the Term in accordance with this Agreement; 
 WHEREAS, Aventis agrees to manufacture and supply to Purchaser Products for sale and distribution in the Territory upon the terms and subject to the
conditions provided herein; and 
 WHEREAS, an Affiliate of Aventis and Purchaser are entering into the Canadian Finished Product Supply
Agreement (the “Canadian Supply Agreement”) dated the date hereof for the supply of Finished Goods for sale and distribution in Canada. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth in this Agreement, and for other good and valuable consideration, the receipt of which are hereby acknowledged, the parties hereto
hereby agree as follows: 

 ARTICLE 1 
 DEFINITIONS 
 The following terms shall have the meanings set forth below. Unless the context
indicates otherwise, the singular shall include the plural and the plural shall include the singular. 
 1.1 “Act” means the
United States Federal Food, Drug and Cosmetic Act, as amended. 
 1.2 “Affiliate” means a person or entity that, directly or
indirectly, through one or more intermediates, controls, is controlled by, or is under common control with the person or entity specified. For the purposes of this definition, control shall mean the direct or indirect ownership of (i) in the
case of corporate entities, securities authorized to cast more than fifty percent (50%) of the votes in any election for directors, or (ii) in the case of non-corporate entities, more than fifty percent (50%) ownership interest with
the power to direct the management and policies of such non-corporate entity. 
 1.3 “Agreement” means this Finished Product
Supply Agreement and all schedules and annexes attached hereto. 
 1.4 “API Supply Agreement” has the meaning set forth in
the Recitals. 
 1.5 “Applicable Laws” means any Law applicable to the ownership, testing, development, manufacture,
package, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of Products. 
 1.6 “Bulk Compound” has the meaning set forth in the Recitals. 
 1.7 “Business Day” means a day
other than Saturday, Sunday or any day on which a commercial bank in New York, New York or Montreal, Canada is authorized to close. 
 1.8 “Carafate ® Suspension
Product” means the pharmaceutical product (sucralfate) in a suspension formulation and more particularly identified by NDA 19-183, and sold under a Product Trademark. 
 1.9 “Carafate ® Tablet
Product” means the pharmaceutical product (sucralfate) in a tablet formulation and more particularly identified by NDA 18-333, and sold under a Product Trademark. 
 1.10 “cGMP” means current Good Manufacturing Practices (i) as promulgated under the Act at 21 CFR (chapters 210 and 211), as the
same may be amended or re-enacted from time to time and (ii) as required by Law in Canada. 
 1.11 “Closing Date” has
the meaning set forth in the Product Acquisition Agreement. 
 1.12 “Discretionary Manufacturing Changes” has the meaning
set forth in Section 2.7(b). 
  

 - 2 - 

 1.13 “Effective Date” means the Closing Date. 
 1.14 “FDA” means the United States Food and Drug Administration or any successor agency thereof. 
 1.15 “Force Majeure” has the meaning set forth in Section 10.3. 
 1.16 “Governmental Authority” means any national, provincial, regional, state, local or other judicial, legislative, executive,
administrative or regulatory entity or authority. 
 1.17 “Indemnitee” has the meaning set forth in Section 9.3(a).

 1.18 “Indemnitor” has the meaning set forth in Section 9.3(a). 
 1.19 “Initial Product Costs” has the meaning set forth in Section 3.1. 
 1.20 “Law” means any law, common law, statute, rule, regulation, ordinance, order, writ, judgment, injunction, decree, stipulation,
determination, award or requirement of any Governmental Authority. 
 1.21
“NDA” means a New Drug; Application pursuant to Section 505 of the Act (21 U.S.C. Section 355), including any
supplements, amendments or modifications submitted to or required by the FDA or any successor application or procedure or any foreign equivalent of a U.S. New Drug Application for approval to market, including, where applicable, applications for
labeling, pricing and reimbursement approval. 
 1.22 “Prime Rate” has the meaning set forth in Section 3.2(a).

 1.23 “Product” means the finished product forms of the pharmaceutical product (sucralfate) in a tablet and suspension
formulation and more particularly defined in NDAs 18- 333 and 19-183, respectively. 
 1.24 “Product Acquisition Agreement”
has the meaning set forth in the Recitals. 
 1.25 “Product Approval” means all Regulatory Approvals material to, or legally
required for, the development, testing (including the conduct of clinical trials), manufacturing, processing, distribution, marketing, storage, labeling, packaging, promotion, sale, offer for sale or use of any Products. 
 1.26 “Regulatory Approval” means all licenses, permits, waivers, consents, certificates, registrations, approvals (including without
limitation, approvals of NDAs and INDs, pricing and third party reimbursement approvals and labeling approvals) of, with or from any Governmental Authority. 
 1.27. “Required Manufacturing Changes” has the meaning set forth in Section 2.7(a). 
  

 - 3 - 

 1.28 “Specifications. “ means the written specifications for Product as set forth in
applicable NDAs, as the same may be amended from time to time pursuant to the terms of this Agreement. 
 1.29 “Technical
Agreement” has the meaning set forth in Section 5.9. 
 1.30 “Term” has the meaning set forth in
Section 4.1. 
 1.31 “Territory” means the United States, its territories and possessions, including without
limitation, the Commonwealth of Puerto Rico. 
 1.32 “Third Party Claim” has the meaning set forth in Section 9.3(a).

 1.33 “Third Party Liabilities” has the meaning set forth in Section 9.1. 
 ARTICLE 2 
 MANUFACTURE, PURCHASE
AND SALE OF PRODUCT 
 2.1 Supply. Pursuant to the terms and conditions of this Agreement, during the Term, Aventis agrees to
supply or have supplied Products for Purchaser. Purchaser agrees to purchase, or cause to be purchased, exclusively from Aventis or its permitted designee, Purchaser’s requirement of Products for purposes of distribution by Purchaser in the
Territory. 
 2.2 Forecasts. 
 (a) Long-Range Forecasts. Within ninety (90) days after the Effective Date, and by
July 1st of each calendar year for the Term or any renewals or extensions thereof, Purchaser shall furnish Aventis with a quarterly long-range
forecast of the quantities of each Product that Purchaser intends to order for the shorter of (i) the remaining Term or (ii) three (3) years. Such forecasts shall represent the most current estimates for planning purposes, but shall
not be purchase commitments. Such forecasts shall not exceed Aventis’ maximum monthly and annual capacity as set forth in Section 2.6(a), unless a forecast in excess of Aventis’ maximum monthly and annual capacity is mutually agreed
to in writing by the parties. 
 (b) Short Term Rolling Forecasts. In addition
to the non-binding, long-range forecasts provided for in Section 2.2(a), within sixty (60) days after the Effective Date and, at least four (4) months prior to the first day of each calendar month thereafter (it being understood that
Purchaser shall utilize Aventis’ scheduled firm orders for the first four (4) months of this Agreement, as previously described to Purchaser and attached hereto as Schedule 2.2(b), and it being further understood that the scheduled
firm orders for January, February, March and April of 2004 with respect to the Carafate ® Suspension Product shall be zero (0) because of a temporary production shutdown at
Aventis’ facility during these months), Purchaser shall furnish Aventis with a rolling forecast of the quantities of Product that Purchaser intends to order by month during the eighteen (18) month period commencing with that calendar month
or such shorter period as remains in the Term. Such forecasts shall be broken down into Product type, quantities and shipping dates. Such forecasts shall not exceed Aventis’ maximum monthly and annual capacity limitations as set forth in
Section 2.6(a). Except as otherwise provided herein, Purchaser shall be required to purchase one hundred percent (100%) of the amount of Products forecast for the first four (4) months of each rolling forecast. 
  

 - 4 - 

 (c) If Aventis notifies Purchaser in writing
within ten (10) Business Days after Purchaser’s delivery of a rolling forecast, Aventis shall be entitled to reject that portion of the order in a rolling forecast with respect to the Carafate® Suspension Product, and require Purchaser to submit a revised rolling forecast with respect to the Carafate® Suspension Product, if such rolling
forecast fails to meet the following parameters with respect to the Carafate® Suspension Product (and Purchaser shall have no purchase obligations under the rejected forecast): 

 

			
	 Month of Any Given Rolling Forecast with
respect to the
Carafate® Suspension
Product
	  	 Permissible Increase or Decrease of Product (in full batch quantities)
Compared to the Quantity
Specified in the Rolling Forecast Delivered the Previous Month

	Months 1,2, 3	  	N/A
		
	Months 4, 5, 6 and 7	  	No less than 75% and no more than 125% of months 5, 6, 7 and 8, collectively, of the previous forecast.
		
	Months 8, 9, 10 and 11	  	No less than 50% and no more than 150% of Months 9,10, 11 and 12, collectively, of the previous forecast.
		
	months 12 through 18	  	N/A

 (d) Each monthly forecast set forth in the
rolling forecasts delivered to Aventis must be in full batch quantities for the Carafate® Suspension Product and the Carafate®
Tablet Product, respectively (i.e. Purchaser may not forecast a partial batch even if permissible pursuant to the table set forth in Section 2.2(c) above). The batch quantities are set forth on Schedule 2.6. Aventis shall be entitled to
reject that portion of the order in a rolling forecast with respect to the Carafate® Suspension Product and/or the Carafate®
Tablet Product, respectively, and require Purchaser to submit a revised rolling forecast with respect to the Carafate® Suspension Product and/or the Carafate® Tablet Product, if the forecast for any given month for such Product in such rolling forecast is not in a full batch quantity (and Purchaser shall have no purchase obligations under the rejected forecast).

 (e) In no event shall Aventis be required to supply orders in excess of the maximum monthly or annual capacity as set forth in
Section 2.6(a), and following: (i) the assignment of the API Supply Agreement to Purchaser; or (ii) Purchaser otherwise sourcing directly the Bulk Compound, Aventis shall not be responsible or otherwise required to accept any purchase
order to the extent of an insufficient supply of Bulk Compound. 
  

 - 5 - 

 2.3 Firm Orders. 
 (a) Purchaser shall place purchase orders with Aventis for Products to be delivered for the first four (4) months of each rolling forecast. All purchase orders must be received by Aventis at least four
(4) months prior to the delivery date specified in each respective order. Purchaser acknowledges that Products are produced in full batch quantities. Such orders shall be in full batch quantities and when combined with all other purchase orders
for the applicable four (4) month period are at least as great and no greater than the amount required to be purchased by Purchaser pursuant to Section 2.2 for each Product. In addition, the number of such purchase orders shall not exceed
one (1) per month for each Product, unless a greater monthly number is agreed to by Aventis, and, to the extent possible, shall be delivered to Aventis on or about the fifteenth (15th) of such month. Each purchase order shall specify the
delivery schedule within the month and Aventis shall deliver against each such purchase order in accordance with Section 2.4. Purchaser shall be obligated to purchase all such Products ordered and delivered by the delivery date specified in
Purchaser’s purchase order, provided that such Products meet the Specifications. Unless otherwise specified in: writing by Aventis, all orders placed by Purchaser with Aventis hereunder shall be addressed as follows: 
  

			
	Aventis Pharmaceuticals Inc.
	10236 Marion Park Drive
	Kansas City, MO 64137-1405
	Attn: Jim Westberg, Planning Leader
	Mail: P.O. Box 9720 C3-0960, Kansas City, MO 64134-9720
	Fax: (816) 966-5209
	Telephone: (816) 966-4245

 (b) Any purchase orders, purchase order releases, confirmations, acceptances, advices and similar
documents submitted by either party in conducting the activities contemplated under this Agreement are for administration purposes only and shall not add to or modify the terms of this Agreement. To the extent of any conflict or inconsistency
between this Agreement and any such document, the terms and conditions of this Agreement shall control as to a particular order unless otherwise agreed to in writing by the parties. 
 2.4 Delivery. 
 (a) Aventis shall meet
the delivery dates and order quantities indicated in Purchaser’s binding and accepted firm orders for all Products. Any shipment delivered that is within plus or minus ten percent (+/-10%) of the quantity ordered and/or plus or minus five (+/-
5) Business Days of the delivery date specified on the relevant firm order will be considered as delivered on time. Subject to the provisions of Section 2.5 and Section 10.3, if Aventis fails to deliver such shipment within
five (5) Business Days after the delivery date specified on the relevant firm order, Aventis shall use reasonable best efforts to deliver the shipment (within plus or minus ten percent (+/-10%) of the quantity ordered) in a prompt manner
thereafter, provided, however, that nothing in this sentence shall limit the rights and remedies of Purchaser hereunder. 
 (b) Delivery
terms for Product shall be EXW (Incoterms 2000) Aventis’ manufacturing facility, warehouse or such other facility mutually agreed to by the parties. Title and risk of loss shall pass to Purchaser once the Product is placed on the loading dock

  

 - 6 - 

 
of Aventis’ facility. Purchaser shall be responsible for all freight, insurance, handling, fees, taxes and other costs associated with the shipment of
Product, as well as all export licenses, import licenses and customs formalities for the import and export of goods. 
 2.5 Rejected
Goods/Shortages. 
 (a) Notice; Replacement. Purchaser shall notify Aventis in writing of (i) any claim relating to any
Product that fails to meet the Specifications, or (ii) any shortage in quantity of any shipment of any Product as soon as reasonably practical, but not later than thirty (30) days (or forty-five (45) days in the event an outside
testing laboratory is used) of receipt of such Product. Purchaser shall be deemed to have accepted the Product if it does not provide Aventis written notice of such shortfall or failure to meet Specifications within such thirty (30) day period
(or forty-five (45) days in the event an outside testing laboratory is used). If the parties agree that such Product is defective or that there is a shortage, Aventis shall replace the defective Product or use its commercially reasonable
efforts to make up the shortage at the next practical delivery date, at no additional cost to Purchaser. Purchaser shall make arrangements with Aventis for the return or disposal of any rejected Product; the costs of such return or disposal shall be
paid by Aventis. In the event that only a limited supply of Product is available to replace or supply such rejection or shortage, then Aventis shall ship to Purchaser such quantities of Product as are available and Purchaser will be promptly
reimbursed or credited against future orders, at Purchaser’s option, for amounts paid for the remaining quantity of rejected Product. 
 (b) API Allocation. During the period prior to (i) the assignment of the API Supply Agreement to Purchaser; or (ii) Purchaser otherwise sourcing directly the Bulk Compound, if Aventis is not able to meet firm orders on
forecasts due to a shortage of Bulk Compound, Aventis shall promptly notify Purchaser of such shortage of Bulk Compound, and, if possible, the date such shortage of Bulk Compound is expected to end. In such event, Aventis shall allocate its
available supply of Bulk Compound in such proportion as the quantity of Bulk Compound used to supply Product over the immediately preceding 12-month period bears to the total quantity of Bulk Compound used to supply other products over the
immediately preceding 12-month period. Following the assignment of the API Supply Agreement or upon Purchaser otherwise sourcing directly the Bulk Compound’ Aventis shall have no further obligation to allocate Bulk Compound as set forth herein
and Aventis shall not be entitled to allocate the Bulk Compound sourced by Purchaser. 
 (c) Disputes. If Aventis disagrees with
Purchaser’s claim that such Product fails to meet the applicable Specifications, Aventis and Purchaser representatives shall attempt to resolve such dispute. If the representatives cannot resolve such dispute within fifteen (15) days, a
sample of such Product shall be submitted by Aventis and Purchaser to a mutually agreed-to qualified laboratory for testing against the Specifications and the test results obtained by such laboratory shall be final and controlling. The fees and
expenses of such laboratory testing shall be borne entirely by the party whose Product analysis was in error. In the event the test results indicate that the Product in question does not conform to the Specifications, Aventis shall replace such
Product at no additional cost to Purchaser as soon as reasonably possible after receipt of such results; provided, however, Aventis shall have no liability to Purchaser if Product fails to meet the Specifications if the Product:
(i) has been tampered with or otherwise altered other than by 

  

 - 7 - 

 
Aventis; (ii) has been subject to misuse, negligence or accident other than by Aventis; or (iii) has been stored, handled or used in a manner
contrary to applicable regulatory requirements other than by Aventis. 
 (d) Sole Remedy. The provisions of Sections 2.5(a) in the
case of shortage in quantity of any shipment of Product, and except as otherwise provided in Section 9.2(a) herein with respect to Third Party Claims, Sections 2.5(a) and (b), in the case of Product that fails to meet the Specifications, shall
be the sole remedy available to Purchaser with respect to any shortage in quantity of any shipment of Product, or Product that fails to meet the Specifications, as the case may be. 
 2.6 Capacity. Aventis’ maximum monthly and annual capacity to manufacture Product is set forth on Schedule 2.6. 
 2.7 Manufacturing Changes. 
 (a)
Required Manufacturing Changes. For changes to the Specifications or manufacturing processes that are required by Applicable Laws (collectively “Required Manufacturing Changes”), Aventis and Purchaser shall cooperate in
making such changes and use commercially reasonable efforts to implement such changes in compliance with such Applicable Laws and as promptly as practicable. Notwithstanding the foregoing, Aventis’ standard change control procedures shall be
utilized in reviewing such changes. 
 (b) Discretionary Manufacturing Changes. For changes to the Specifications or manufacturing
process that are not Required Manufacturing Changes (collectively “Discretionary Manufacturing Changes”), Aventis and Purchaser must each agree to any Discretionary Manufacturing Changes and shall, to the extent commercially
reasonable under the circumstances, cooperate in making such changes, and each agrees that it shall not unreasonably withhold its consent to such Discretionary Manufacturing Changes. Notwithstanding the foregoing, Aventis’ standard change
control procedures shall be utilized in reviewing such changes. 
 (c) Manufacturing Changes. Notwithstanding the foregoing, all
internal and external costs, including, without limitation, obsolete raw materials, regulatory filings, work-in- process, Product, packaging and labeling materials (i) associated with Required Manufacturing Changes relating solely to Product in
the Territory shall be borne by Purchaser, (ii) associated with Required Manufacturing Changes relating solely to Product outside the Territory shall be borne by Aventis, (iii) associated with Required Manufacturing Changes for Product
both inside and outside the Territory shall be shared based upon the percentage of sales of each Product affected by such Required Manufacturing Change, and (iv) all costs associated with Discretionary Manufacturing Changes shall be borne by
the party initiating such changes. Notwithstanding the foregoing, (i) in the event that a Required Manufacturing Change applies generally to the manufacturing facility of Aventis or operations thereat and not solely to the Product, such costs
shall be borne by Aventis and (ii) the costs of any Required Manufacturing Change required by Applicable Laws in Canada shall be apportioned pursuant to the terms of the Canadian Supply Agreement. 
  

 - 8 - 

 2.8 Labeling and Packaging. Purchaser shall be responsible for all costs of developing new
packaging and labeling for the Product, including without limitation obsolete inventory of packaging and labeling materials’ and shall provide Aventis all art work from vendors selected by Purchaser and pharmacological information, usage
instructions and warnings to be applied to each Product, which shall be consistent with the FDA or Governmental Authority approved labeling for the Product. Purchaser shall provide such information pursuant to this Section 2.8 to Aventis a
sufficient period of time in advance of delivery requirements for the Product set forth in this Agreement. 
 2.9 Appointment of
Sublicensees or Subcontractors. Subject to the provisions of the Technical Agreement pertaining to change control, Aventis may elect to appoint an Affiliate or third party as sublicensee or subcontractor for the purpose of undertaking any
activities reasonably necessary for Aventis to fulfill its obligations of manufacturing and supplying Product hereunder; provided, however, that such Affiliate or third party is subject to a written agreement that subjects such
Affiliate or third party to all relevant provisions, requirements, restrictions and limitations in this Agreement that pertain to Aventis; arid provided further, however that if the sublicensing or subcontracting of such activities
would require notice to be delivered to the FDA, Aventis shall be required to obtain the consent of Purchaser prior to sublicensing or subcontracting such activity (which consent shall not be unreasonably withheld, conditioned or delayed).

 2.10 Assignment of API Supply Agreement. Upon assignment of the API Supply Agreement, Purchaser shall be responsible for supplying
Aventis with all quantities of Bulk Compound necessary to manufacture the Product as contemplated under this Agreement. Purchaser shall supply all such quantities of Bulk Compound at such delivery dates forecasted and ordered by Aventis in order to
meet the forecasting and delivery schedules of Product set forth herein. Aventis shall have no liability for any disruption in the supply of Product to Purchaser which is caused by any delay by Purchaser in delivering quantities of Bulk Compound
which meet the applicable specifications therefor to Aventis. Any Bulk Compound delivered to Aventis which does not meet applicable specifications shall be removed and disposed of by Purchaser, at Purchaser’s cost, and expense, as soon as
practical after the determination of non- compliance. Purchaser shall supply the Bulk Compound (together with the appropriate certificate of analysis) to Aventis without charge and shall bear all freight charges and risk of loss in transit. Until
such time as the API Supply Agreement has been assigned to Purchaser, Purchaser shall not be permitted to source Bulk Compound from any third party for use in the Product without the prior written consent of Aventis. 
 2.11 API Projections. After the assignment of the API Supply Agreement to Purchaser, Aventis shall deliver to Purchaser relevant information
regarding the Bulk Compound in connection with the manufacture of Products hereunder, in order to assist Purchaser in forecasting the Bulk Compound necessary to manufacture the Products hereunder. 
  

 - 9 - 

 ARTICLE 3 
 PRICING AND PAYMENT 
 3.1 Pricing. 
 (a) The initial costs payable to Aventis by Purchaser for the Product shall be as set forth on Schedule 3.1 (together, the “Initial Product
Costs”) The Initial Product Costs for the Carafate Suspension Product are based upon an annual volume of supply of at least [ ** ] units (the ‘Minimum Annual Volume”) On [ ** ] and on [ ** ] of each calendar year
thereafter, Aventis shall determine the volume of the Carafate Suspension Product sold under this Agreement in the immediately prior calendar year and, to the extent such amount is less than the Minimum Annual Volume, Aventis shall provide Purchaser
a written notice (the “Price Adjustment Notice”) indicating the increased fixed cost of the Carafate Suspension Product as a result of not meeting such Minimum Annual Volume. To the extent that the volume of the Carafate Suspension
Product sold hereunder is less than the Minimum Annual Volume, Purchaser shall pay Aventis a lump sum amount to compensate Aventis for the increased fixed cost of supply of the Carafate Suspension Product, as reasonably determined by Aventis and as
set forth in the Price Adjustment Notice. Such lump sum payment shall be due and payable no later than ten (10) days following delivery by Aventis of the Price Adjustment Notice. 
 (b) The Initial Product Costs will remain firm until [ ** ]. Beginning on [ ** ] and on [ ** ] of each calendar year thereafter, the Initial Product Cost
shall be increased to reflect increases in the [ ** ] for the calendar year prior to the year for which any such adjustment is to take place. 
 (c) In addition to the foregoing adjustments, if Aventis’ documented costs of materials increase at any time (other than increases to the price of the Bulk Compound), then Aventis shall also have the additional right to increase the
Initial Product Costs by [ ** ]; provided, however, Aventis shall provide written proof of same to Purchaser. 
 (d) In the
event that Purchaser exercises the Extension Option pursuant to the terms of Section 4.1, the Initial Product Costs shall be increased by Aventis as set forth on Schedule 3.1. 
 3.2 Payment. 
 (a) Terms. All
payments required by this Agreement shall be made in United States Dollars by wire transfer to an account designated by Aventis. All invoices are to be paid in full without any setoff or deduction and payment must be received within thirty
(30) days from the date of invoice. The date of each invoice shall be the date the Products are available for shipment pursuant to Section 2.4. Payment shall be made without deduction, deferment, set-off, lien or counterclaim of any
nature, other than for rejected or returned goods for which a credit acknowledgment has been issued by Aventis or with respect to which the parties are in dispute pursuant to Section 2.5. Time for payment shall be of the essence. Interest shall
accrue on any amount overdue, at the lesser of (i) the annual prime rate as reported by the Wall Street Journal, New York Edition, or any other reputable publication mutually agreed to by the parties (the “Prime Rate”)
on the date such payment is due, plus an additional five percent (5%) or (ii) the maximum annual rate permitted by Law, such interest to begin accruing on a daily basis from the date of invoice, and shall accrue both before and after
judgment; provided, however, in the case of a good faith dispute regarding payment resolved to be due and not paid within three (3) 

  

 - 10 - 

 
Business Days after such resolution, such interest shall begin accruing on a daily basis from the date such payment becomes overdue, and shall accrue both
before and after judgment; provided. further, in the case of a good faith dispute regarding payment, Purchaser may in its discretion determine to pay such amounts disputed to be overdue and in the event amounts are finally determined
not to be due by Purchaser, Aventis shall repay such excess amounts to Purchaser determined not be due with interest thereon as calculated pursuant this section. The foregoing interest shall begin to accrue and be payable to Aventis (or Purchaser,
as the case may be) without notice. 
 (b) Default. With respect to defaults of payment not cured within fifteen (15) Business
Days after receipt of written notice from Aventis to Purchaser, Aventis shall, in its sole discretion, and without prejudice to any other of its accrued rights, be entitled to suspend the provision of the Product or to treat this Agreement as
repudiated by notice in writing to Purchaser exercised at any time thereafter; provided, however, a good faith bona fide dispute by Purchaser regarding a payment pursuant to this Agreement shall not be considered a default of payment
so long as Purchaser notifies Aventis in writing of such dispute within the later of five (5) Business Days from the date of invoice or the date of payment. Purchaser acknowledges it will notify Aventis promptly upon a determination that a
dispute exists regarding a payment. 
 ARTICLE 4 
 TERM AND TERMINATION 
 4.1 Term Supply of Product. The Term will commence upon the Effective
Date and will continue for a five (5) year period, unless terminated earlier in accordance with the provisions of Section 4.2 (the “Term”). In the event that this Agreement has not been previously terminated and Purchaser
is not in material default hereunder at the time it is requesting an extension but solely to the extent Aventis has provided prior written notice of such material default to Purchaser, Purchaser shall have the option to extend the Term hereunder for
an additional two (2) year period upon not less than twelve (12) months written notice to Aventis prior to the end of the initial five (5) year term (the “Extension Option”). If Purchaser elects to exercise the
Extension Option, then the “Term” shall be deemed to include such additional two (2) year period. 
 4.2 Early
Termination. Either Purchaser or Aventis may terminate this Agreement forthwith by notice in writing to the other party upon the occurrence of any of the following events: 
 (a) if the other party commits a material breach of this Agreement, other than a payment default, which in the case of a breach capable of remedy shall
not have been remedied within thirty (30) days of the receipt by the other party of a written notice identifying the breach and requiring its remedy or such longer time as the party in breach may demonstrate to the other party is reasonably
necessary to remedy the breach using its commercially reasonable efforts to do so; 
  

 - 11 - 

 (b) if the other party ceases for any reason to carry on business, but not as the result of a merger,
acquisition or reorganization with one or more entities whether in a single transaction or a series of transactions, or convenes a meeting of its creditors or has a receiver or manager appointed in respect of all or substantially all of its assets
or is the subject of an application for an administration order or of any proposal for a voluntary arrangement or enters into liquidation, whether compulsorily or voluntarily or undergoes any analogous act or proceedings under foreign Law;

 (c) the enactment of any Law that would render it impossible for the other party to perform its obligations hereunder; 
 (d) after the third anniversary of the Effective Date of this Agreement, Purchaser may provide not less than twelve (12) months prior written notice
to Aventis of its election to terminate (e.g., the earliest the Agreement could be terminated would be the fourth anniversary of this Agreement); or 
 (e) in the event that Aventis fails to make any of the required deliveries as set forth in Section 2.4 as a result of Force Majeure, and such failure continues for three (3) consecutive months, Purchaser may
then immediately terminate this Agreement by providing written Notice to Aventis. 
 4.3 Consequences of Termination and Survival.
Termination of this Agreement for whatever reason shall not affect the accrued rights and obligations of either Aventis or Purchaser arising under or out of this Agreement. The obligations under Article 6 (Product Recalls), Article 7 (Warranties),
Article 8 (Nondisclosure and Confidentiality), Article 9 (Indemnification and Insurance), Article 10 (Dispute Resolution) or any other provision which expressly or by implication is intended to survive expiration or termination shall survive
expiration or termination of this Agreement as provided in such sections. 
 4.4 Accrued Obligations. Upon the expiration or earlier
termination of this Agreement, Purchaser shall pay to Aventis: (i) all amounts outstanding and remaining to be paid for services related to Product supplied prior to the expiration or termination; (ii) all binding amounts for services
related to Product forecasted pursuant to Section 2.2 or ordered pursuant to Section 2.3 prior to the expiration or termination; provided, Aventis delivers such Product in accordance with the Specifications; and provided further
that this clause (ii) shall not apply in the event of a breach of this Agreement by Aventis, (iii) an amount to compensate Aventis at its actual out-of-pocket costs for all raw materials that Aventis has purchased in reliance on
Purchaser’s rolling forecasts, in which case Aventis shall transfer such raw materials to Purchaser; and (iv) purchase from Aventis all remaining inventory of Product which meets Specifications. 
 4.5 Assistance at Termination. Upon expiration or the earlier termination of this Agreement by Purchaser pursuant to Section 4.2 above,
Aventis shall transfer to Purchaser, all regulatory information and other information and materials reasonably necessary for Purchaser or its designee to perform the manufacturing activities undertaken by Aventis under this Agreement, and the
parties shall establish such operational procedures as are reasonably necessary for Purchaser to perform such manufacturing activities. In connection with the foregoing, during the nine (9) month period prior to the termination of the
Agreement: (i) upon reasonable 

  

 - 12 - 

 
request, Purchaser shall be permitted to consult with Aventis’ technical personnel on the specified manufacturing activities; and (ii) Purchaser
shall be permitted to send no more than five employees or representatives to Aventis’ manufacturing facilities to observe Aventis’ performance of its manufacturing activities in actual practice for a period of not more than ten
(10) Business Days during such nine (9) month period. In no event shall Aventis be required to send any of its personnel to Purchaser’s or its designees’ locations. Purchaser shall bear the reasonable costs and expenses incurred
by Aventis in connection with facilitating the transfer of any manufacturing activities to Purchaser, including: (i) the internal cost of any Aventis personnel providing any of the services required hereunder calculated on the basis of
Aventis’ then current FTE rates; and (ii) cost of any samples or materials provided by Aventis, together with any handling costs associated therewith. 
 ARTICLES 5 
 CERTIFICATES, ACCESS AND REGULATORY MATTERS 
 5.1 Testing; Certificate of Analysis. Aventis shall perform, or cause to be performed, the tests required to be performed by Aventis pursuant to
the Technical Agreement on each lot of Product manufactured pursuant to this Agreement before delivery to Purchaser. Each test report shall set forth the items tested, Specifications and test results in a certificate of analysis, containing the
types of information which shall have been approved by mutual agreement of the parties, for each lot delivered. Aventis shall send, or cause to be sent, such certificates to Purchaser simultaneously with delivery of each lot unless otherwise agreed.
For purposes of clarity all such testing costs are for Aventis’ account and are included in the prices set forth on Schedule 3.1. 
 5.2 Notice of Failure to Meet Specifications. Upon Aventis’ discovery that any batch or lot of Product fails to conform to the applicable Specifications, Aventis will notify Purchaser in writing within five (5) Business
Days of such failure to meet the applicable Specifications and of the nature thereof. Aventis shall investigate all such failures promptly and determine the cause for the failure and a corrective action to prevent future failures. 
 5.3 Records. During the Term of this Agreement and for the time periods required by Applicable Law, Aventis shall prepare and maintain batch
records to include all manufacturing, packaging, quality control analytical and stability records, all records of shipment, and all validation data relating to the Product, including without limitation all data related to raw materials and packaging
materials. 
 5.4 Governmental Inspections. Aventis shall advise Purchaser immediately upon receiving a notice that an authorized
agent of a Governmental Authority will visit or inspect its facilities where the Product is being manufactured, processed, packaged, labeled, tested or stored. Aventis shall furnish to Purchaser all material information supplied to, or supplied by,
any Governmental Authority, including, without limitation, any Notice of Inspection, Form 483 observations and warning letters, untitled letters, to the extent that such reports or letters relate to Product, or the ability of Aventis to supply such
Product, within five (5) Business Days of their receipt of such information or delivery of such information, as the case may be. Aventis shall be responsible for responding to all such 

  

 - 13 - 

 
notices, forms or letters, except that Aventis shall provide such responses to Purchaser, to the extent feasible, at least three (3) Business Days prior
to submission to any Governmental Authority and shall incorporate such reasonable and timely revisions as suggested by Purchaser. 
 5.5
Access to Facilities. Except as otherwise provided herein, upon the reasonable prior written request of Purchaser; and upon Purchaser’s (and Purchaser’s designated representative, if applicable) execution of any confidentiality
agreements required by Aventis, Aventis shall permit Purchaser and/or Purchaser’s designated representatives the right to inspect and visit once per calendar year those portions of the manufacturing, storage and testing facilities of Aventis
where Product is being manufactured, stored or tested, as the case may be, during regular business hours, to ascertain compliance with this Agreement, the Technical Agreement, cGMPs and the Specifications, it being agreed that in the event Aventis
delivers any Product not in compliance with Specifications, Purchaser shall have the right to inspect such facilities more frequently, during reasonable business hours, and upon reasonable prior notice, until any issues related to the delivery of
such non-conforming Product are resolved. 
 5.6 Product Inquiries and Complaints. Purchaser will promptly submit to Aventis copies of
all Product safety and efficacy inquiries, Product quality complaints and adverse drug event reports received by it, together with all relevant evidence and other information relating thereto, in accordance with procedures to be agreed upon by the
parties. Except as otherwise required by Applicable Law, Purchaser will be responsible for investigating and responding to all such inquiries, complaints and adverse events regarding Product. It shall be the responsibility of Purchaser to comply
with all Applicable Law regarding adverse drug events and, except as otherwise provided herein, Product quality matters. Subject to confidentiality obligations, Aventis agrees, upon the reasonable request of Purchaser, to provide all relevant
information in its possession or control relating to such complaint, inquiry or adverse event, to assist in such compliance. 
 5.7
Response to Complaints and/or Adverse Drug Events. Pursuant to a reported complaint and/or adverse drug event, if the nature of the reported complaint and/or adverse drug event requires testing, Aventis will, at Purchaser’s reasonable
request, perform analytical testing of corresponding retention samples and provide the results thereto to Purchaser as soon as reasonably practicable. Such testing shall be performed using testing procedures as set forth in Applicable Law or Product
Approval or otherwise required by applicable Governmental Authorities. If it is determined that Aventis is responsible for such reported complaint and/or adverse drug event, then Aventis shall bear the reasonable cost of such testing. Otherwise,
Purchaser shall pay the reasonable cost associated with such testing. 
 5.8 Additional Information. Purchaser shall be responsible
for assuring that all promotional material produced by it relating to Products comply with Applicable Laws. Purchaser shall provide to Aventis a copy of each FDA or any other Governmental Authority annual report and any additional regulatory
information, including, without limitation, manufacturing and testing documentation. 
 5.9 Technical Agreement. Each party shall
perform the duties required of it pursuant to a technical agreement to be entered into by the parties within ninety (90) days of the Effective Date (the “Technical Agreement”). To the extent the Technical Agreement either
conflicts with this Agreement or is silent on an issue addressed, this Agreement shall control. 
  

 - 14 - 

 5.10 Regulatory Compliance. Purchaser shall maintain in full force and effect during the term of
this Agreement all Product Approvals required by Applicable Law. 
 ARTICLE 6 
 PRODUCT RECALLS 
 6.1 Product Recalls. In the event (i) any
Governmental Authority issues a request, directive or order that Product be recalled, (ii) a court of competent jurisdiction orders such a recall, or (iii) Purchaser shall reasonably determine that Product should be recalled, the parties
shall take all appropriate corrective actions, and shall cooperate in the investigations surrounding the recall. In the event that Purchaser determines that Product should be recalled, Purchaser shall consult with Aventis prior to taking any
corrective actions. In the event that such recall results from any cause or event other than that arising from the defective manufacture, testing, storage, packaging or handling by Aventis, excluding defects relating to packaging or labeling
supplied by or prepared at the direction of Purchaser, of the recalled Product, Purchaser shall be responsible for all documented out-of-pocket expenses of such recall consistent with directions, if any, received from the appropriate Governmental
Authority. In the event that such recall results from any cause or event arising from the defective manufacture, testing, storage, processing, packaging or handling, excluding defects relating to packaging or labeling of the Product supplied by or
prepared at the direction of Purchaser, by Aventis, then Aventis shall be responsible for all such documented out-of-pocket expenses of such recall consistent with directions, if any, received from the appropriate Governmental Authority and Aventis
shall promptly replace, at no cost, Product which conforms to the Product Specifications in accordance with Section 2.5. For purposes of this Agreement, the expenses of recall shall include the expenses of notification and destruction or return
of the recalled Product and all other documented out-of-pocket costs incurred in connection with such recall, but shall not include lost profits or opportunity costs of either party. 
 6.2 Disputes. If there is any dispute concerning which party’s acts or omissions gave rise to such recall of Product, such dispute shall be
referred for decision to an independent expert, (to be selected by both parties hereto) who shall act as an expert and not as an arbitrator. The decision of such independent expert shall be in writing and, except for manifest error on the face of
the decision, shall be binding on both Purchaser and Aventis. The costs of such independent expert shall be borne by the party who is found to be responsible for the recall by the independent expert. After such determination, costs shall be paid by
the responsible party in accordance with Section 6.1. 
  

 - 15 - 

 ARTICLE 7 
 REPRESENTATIONS, WARRANTIES, AND COVENANTS 
 7.1 Compliance with cGMP. Aventis, acting in its
own name and on behalf of its Affiliates, represents warrants and covenants that all Product will be manufactured, tested and handled in compliance with Product Approvals and cGMP. 
 7.2 Conformity with Specifications. Subject to the Bulk Compound supplied to Aventis complying with all relevant specifications, Aventis acting in
its own name and on behalf of its Affiliates, represents warrants and covenants that Product manufactured, tested and handled by Aventis or its Affiliates and sold to Purchaser pursuant to this Agreement will comply with the Specifications and
Technical Agreement at the time of delivery to the common carrier for such Product in effect at the time of manufacture. 
 7.3 Compliance
with the Act. Subject to the Bulk Compound supplied to Aventis complying with all relevant specifications, Aventis acting in its own name and on behalf of its Affiliates, represents warrants and covenants that all Product delivered to Purchaser
pursuant to this Agreement will, at the time of such delivery, not be adulterated within the meaning of the Act and will not be an article which may not, under the provisions of such Act, be introduced into interstate commerce. 
 7.4 No Liens. Aventis, acting in its own name and on behalf of its Affiliates, represents and warrants that all Product delivered to Purchaser
pursuant to this Agreement will, at the time of such delivery, be free and clear of all liens, encumbrances, security interests and other encumbrances. 
 7.5 Compliance with Applicable Laws. During the term of this Agreement, Aventis shall comply in all material respects with all Applicable Laws applicable to the conduct of its business in the performance of
this Agreement. 
 7.6 Exclusion of Other Warranties. EXCEPT WHERE OTHERWISE SET FORTH IN THIS AGREEMENT, SECTIONS 7.1, 7.2, 7.3, 7.4
AND 7.5 ARE IN LIEU OF ALL CONDITIONS, WARRANTIES AND STATEMENTS IN RESPECT OF PRODUCT AND THE SERVICES PROVIDED HEREUNDER, WHETHER EXPRESSED OR IMPLIED BY STATUTE, CUSTOM OF THE TRADE OR OTHERWISE, INCLUDING BUT WITHOUT LIMITATION ANY SUCH
CONDITION, WARRANTY OR STATEMENT RELATING TO THE DESCRIPTION OR QUALITY OF PRODUCT, ITS MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE UNDER ANY CONDITIONS, AND ANY SUCH CONDITION, WARRANTY OR STATEMENT IS HEREBY EXCLUDED. EXCEPT AS
PROVIDED IN ARTICLE 9 WITH RESPECT TO THIRD PARTY CLAIMS, REPLACEMENT OR REFUND OF ANY NONCONFORMING PRODUCT AND REASONABLE DOCUMENTED OUT-OF-POCKET EXPENSES SHALL BE PURCHASER’S SOLE REMEDY FOR BREACH OF ANY PROVISION OF THIS AGREEMENT. Except
for each party’s indemnification obligations pursuant to Sections 9.1 and 9.2 for Third Party Claims and injunctive relief permitted under Section 8.4, in no event shall Aventis or Purchaser and/or their respective Affiliates, be liable
under or with respect to this Agreement, whether due to breach of warranty, tort, or repudiation of any term or condition or otherwise, 

  

 - 16 - 

 
for any indirect, incidental, consequential, special or punitive damages of any kind, including, but not limited to, loss of profits; provided however, in
the event of Aventis’ failure to supply Product in accordance with the terms of this Agreement as a result of its gross negligence or intentional breach of this Agreement, Purchaser shall be entitled to seek loss of profits as its damages for
such intentional breach or gross negligence. 
 ARTICLE 8 
 NONDISCLOSURE AND CONFIDENTIALITY 
 8.1 Nondisclosure Obligations. 
 (a) Section 8.1 Confidential Agreement. For the purposes of this Agreement, the term “Confidential Information” shall mean
any and all information of a party hereto that may be exchanged between the parties at any time and from time to time before and during the Term in relation to the subject matter covered by this Agreement and which is confidential in nature.
Confidential Information as defined herein shall in particular be deemed to include, without limitation, all notes, analyses, compilations, studies, interpretations or other documents, whether in tangible form or on electronic or other data storage
media, prepared by the receiving party and its Representatives (as defined hereinafter), which contain, reflect or are based on, in whole or in part, Confidential Information furnished to the receiving party or its Representatives by the disclosing
party or its Representatives hereunder. 
 (b) Duties of Confidentiality and Non-Use. During the Term, and for a period of ten
(10) years thereafter, each party hereto will maintain in confidence all Confidential Information of the other party. Neither party shall use, disclose or grant use of such other party’s Confidential Information except as required under
this Agreement. To the extent that disclosure is authorized by this Agreement, the disclosing party shall obtain prior agreement from its employees, agents, consultants, Affiliates, subcontractors and sublicensees (collectively, the
“Representatives”) to whom disclosure is to be made to hold in confidence and not make use of such information for any purpose other than those permitted by this Agreement. Each party shall use at least the same standard of care as
it uses to protect its own Confidential Information to ensure that such Representatives do not disclose or make any unauthorized use of such Confidential Information. Each party shall promptly notify the other upon discovery of any unauthorized use
or disclosure of Confidential Information. Confidential Information shall not include any information which: 
 (i) was already known
to the receiving party, other than under an obligation of confidentiality, at the time of disclosure by the other party; 
 (ii) was
generally available to the public or otherwise part of the public domain at the time of its disclosure to the other party; 
 (iii) becomes
generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving party in breach of this Agreement; 
  

 - 17 - 

 (iv) was disclosed to the receiving party, other than under an obligation of confidentiality, by a third
party who had no obligation to the other party not to disclose such information; or 
 (v) was independently developed by the receiving
party without reference to the disclosure by the other party. 
 8.2 Terms of this Agreement. The parties agree not to disclose any
terms or conditions of this Agreement to any third party without the prior consent of the other parties, except (i) as required by Applicable Laws or (ii) to investment bankers of a party or to prospective purchasers of the business or
assets related to the Products; provided such third parties agree to similar confidentiality provisions with respect to the terms and conditions of this Agreement as set forth herein. 
 8.3 Permitted Disclosures. Notwithstanding anything else in this Agreement to the contrary, each party hereto (and each employee, representative,
or other agent of any party) may disclose to any and all persons, without limitation of any kind, the Federal income tax treatment and Federal income tax structure of any and all transaction(s) contemplated herein and all materials of any kind
(including opinions or other tax analyses) that are or have been provided to any party (or to any employee, representative, or other agent of any party) relating to such tax treatment or tax structure, provided, however, that this authorization of
disclosure shall not apply to restrictions reasonably necessary to comply with securities laws. This authorization of disclosure is retroactively effective immediately upon commencement of the first discussions regarding the transactions
contemplated herein, and the parties aver and affirm that this tax disclosure authorization has been given on a date which is no later than thirty (30) days from the first day that any party hereto (or any employee, representative, or other
agent of any party hereto) first made or provided a statement as to the potential tax consequences that may result from the transactions contemplated hereby. 
 8.4 Injunctive Relief. The parties hereto understand and agree that remedies at Law may be inadequate to protect against any breach of any of the provisions of this Article 8 by either party or their employees,
agents, officers or directors or any other person acting in concert with it or on its behalf. Accordingly, each party may be entitled to the granting of injunctive relief by a court of competent jurisdiction against any action that constitutes any
such breach of this Article 8. 
 ARTICLE 9 
 LIMITATION OF LIABILITY, INDEMNIFICATION AND INSURANCE 
 9.1 Indemnification by Purchaser.
Except as otherwise specifically provided herein, Purchaser shall indemnify and hold harmless Aventis and its Affiliates against all third party claims, actions, costs, expenses, including court costs and reasonable legal fees or other third party
liabilities (“Third Party Liabilities”) whatsoever in respect of: 
 (a) the use, marketing, storage, distribution, handling
or sale of Product by Purchaser or its Affiliates; 
  

 - 18 - 

 (b) any gross negligence or willful misconduct by Purchaser and/or its Affiliates otherwise related to
this Agreement; 
 (c) any labeling of any Product to the extent that such labeling has been supplied by or at the direction of Purchaser
and/or its Affiliates and applied in accordance with instructions from Purchaser; and 
 (d) any representation or warranty made by Purchaser
and/or its Affiliates to its customers or users with respect to Product, other than representations or warranties contained in Sections 7.1, 7.2, 7.3, 7.4 or 7.5. 
 9.2 Indemnification by Aventis. Except as otherwise specifically provided herein, Aventis shall indemnify and hold harmless Purchaser against all Third Party Liabilities whatsoever in respect of: 
 (a) any failure by Aventis’ and/or its Affiliates’ to comply with the Specifications, cGMP, or Applicable Laws (provided that, following the
assignment of the API Supply Agreement or the date upon which Purchaser otherwise sources the Bulk Compound, such Third Party Liabilities are not the result of or otherwise arose out of the failure of the Bulk Compound to meet applicable
specifications); 
 (b) any breach of a representation warranty or covenant made by Aventis and/or its Affiliates under this Agreement and/or
the Technical Agreement: and 
 (c) any gross negligence or willful misconduct by Aventis and/or its Affiliates related to this Agreement.

 9.3 Procedures for Indemnification. 
 (a) In the case of a third party claim or demand (“Third-Party Claim”) made by any Person who is not a Party of this Agreement (or an Affiliate thereof) as to which a Party (the
“Indemnitor”) may be Obligated to provide indemnification pursuant to this Agreement, such Party seeking indemnification hereunder (“Indemnitee”) will notify the Indemnitor in writing of the Third-Party Claim (and
specifying in reasonable detail the factual basis for the Third-Party Claim and to the extent known, the amount of the Third-Party Claim) reasonably promptly after becoming aware of such Third-Party Claim; provided, however, that failure to give
such notification will not affect the indemnification provided hereunder except to the extent the Indemnitor shall have been actually prejudiced as a result of such failure. 
 (b) If a Third Party Claim is made against an Indemnitee, the Indemnitor will be entitled, within one hundred twenty (120) days after receipt of
written notice from the Indemnitee of the commencement or assertion of any such Third Party Claim, to assume the defense thereof (at the expense of the Indemnitor) with counsel selected by the Indemnitor and reasonably satisfactory to the
Indemnitee, for so long as the Indemnitor is conducting a good faith and diligent defense. Should the Indemnitor so elect to assume the defense of a Third Party Claim: 
  

 - 19 - 

 (i) the Indemnitor will not be liable to the Indemnitee for any legal or other expenses subsequently
incurred by the Indemnitee in connection with the defense thereof; provided, that if under applicable standards of professional conduct a conflict of interest exists between the Indemnitor and the Indemnitee in respect of such claim, such Indemnitee
shall have the right to employ separate counsel (which shall be reasonably satisfactory to the Indemnitor) to represent such Indemnitee with respect to the matters as to which a conflict of interest exists and in that event the reasonable fees and
expenses of such separate counsel shall be paid by such Indemnitor; provided, further, that the Indemnitor shall only be responsible for the reasonable fees and expenses of one separate counsel (plus local counsels as required) for such Indemnitee;

 (ii) the Indemnitee shall have the right to participate in the defense thereof and to employ counsel, at its own expense, separate from
the counsel employed by the Indemnitor; 
 (iii) the Indemnitor will promptly supply to the Indemnitee copies of all correspondence and
documents relating to or in connection with such Third Party Claim and keep the Indemnitee informed of developments relating to or in connection with such Third Party Claim, as may be reasonably requested by the Indemnitee (including providing to
the Indemnitee on reasonable request updates and summaries as to the status thereof); and 
 (iv) all Indemnitees shall reasonably cooperate
with the Indemnitor in the defense thereof (such cooperation to be at the expense, including reasonable legal fees and expenses, of the Indemnitor). 
 (c) If the Indemnitor does not elect to assume control of the defense of any Third Party Claim within the 120-day period set forth above, or if such good faith and diligent defense is not being or ceases to be
conducted by the Indemnitor, the Indemnitee shall have the right, at the expense of the Indemnitor, after three (3) Business Days notice to the Indemnitor of its intent to do so, to undertake the defense of the Third Party Claim for the account
of the Indemnitor (with counsel selected by the Indemnitee), and to compromise or settle such Third Party Claim, exercising reasonable business judgment. 
 (d) If the Indemnitor acknowledges in writing its obligation to indemnify the Indemnitee for a Third-Party Claim, the Indemnitee will agree to any settlement, compromise or discharge of such Third-Party Claim that the
Indemnitor may recommend, exercising reasonable business judgment, that by its terms obligates the Indemnitor to pay the full amount of Third Party Liabilities (whether through settlement or otherwise) in connection with such Third-Party Claim and
unconditionally and irrevocably releases the Indemnitee completely from all Third Party Liabilities in connection with such Third-Party Claim; provided, however, that, without the Indemnitee’s prior written consent, the Indemnitor shall not
consent to any settlement, compromise or discharge (including the consent to entry of any judgment), and the Indemnitee may refuse to agree to any such settlement, compromise or discharge, that provides for injunctive or other nonmonetary relief
affecting the Indemnitee. If the Indemnitor acknowledges in writing its obligation to indemnify the Indemnitee for a Third-Party Claim, the Indemnitee shall not (unless required by Law) admit any liability with respect to, or settle, compromise or
discharge, such Third-Party Claim without the Indemnitor’s prior written consent (which consent shall not be unreasonably withheld). 
  

 - 20 - 

 9.4 Distribution/Product Liability Insurance. Purchaser shall obtain and maintain in effect for
the Term of this Agreement, liability insurance or indemnity policies with a reputable insurer, in an amount not less than [ ** ] in the aggregate and which policies shall be blanket policies. Such policies shall insure against liability on the part
of Purchaser and any of its relevant Affiliates, as their interests may appear, due to injury, disability or death of any person or persons, or injury to property, arising from the distribution of Product or Products. Upon the execution of this
Agreement and thereafter on within ten (10) Business Days of the beginning of each calendar year during the Term, Purchaser shall provide to Aventis a certificate of insurance (i) summarizing the insurance coverage and
(ii) identifying any exclusions. Purchaser shall promptly notify Aventis of any material adverse alterations to the terms of this policy or decreases in the amounts for which insurance is provided. Promptly after the date hereof, Purchaser and
Aventis agree to work in good faith to determine the insurance provisions necessary to secure the indemnity rights of Aventis hereunder. 
 9.5 Product Liability Claims. As soon as it becomes aware, each party will give the other prompt written notice of any defect or alleged defect in a Product, any injury alleged to have occurred as a result of the use or application
of the Product, and any circumstances that may give rise to litigation or recall of a Product or regulatory action that may affect the sale or manufacture of a Product, specifying, to the extent the party has such information, the time, place and
circumstances thereof and the names and addresses of the persons involved. Each party will also furnish promptly to the other copies of all papers received in respect of any claim, action or suit arising out of such alleged defect, injury or
regulatory action. 
 ARTICLE 10 
 GENERAL PROVISIONS 
 10.1 Notices. 
 (a) Except as otherwise specifically provided, any notice or other documents to be given under this Agreement shall be in writing and shall be deemed to have been duly given if sent by nationally recognized overnight
courier or facsimile transmission to a party or delivered in person to a party at the address or facsimile number set out below for such party or such other address as the party may from time to time designate by written notice to the other:

  

			
	If to Purchaser, to:	  	Axcan Pharma Inc.
		  	597, boulevard Laurier
		  	Mont-Saint-Hilaire, Quebec J3H 6C4
		  	Canada
		  	Attn: General Counsel
		  	Facsimile: (450) 464-9979

  

 - 21 - 

			
	with copies to:	  	Latham & Watkins LLP
		  	Sears Tower, Suite 5800
		  	233 South Wacker Drive
		  	Chicago, Illinois 60606-6401
		  	Attn: Thomas Keim, Jr., Esq.
		  	Facsimile: (312) 993-9767
		
	If to Aventis to:	  	Aventis Pharmaceuticals Inc.
		  	10236 Marion Park Drive
		  	Kansas City, MO 64137-1405
		  	Attn: Vice President, Industrial Operations
		  	Mail: P.O. Box 9720 C3-0960,
		  	          Kansas City, MO 64134-9720
		  	Fax: (816)966-5209
		
	with a copy to:	  	Aventis Pharmaceuticals Inc.
		  	300: Somerset Corp. Blvd.
		  	Mail Stop SC3-820A
		  	Bridgewater, NJ 08807-2854
		  	Facsimile: 908-243-7220
		  	Attn: General Counsel

 (b) Any such notice or other document shall be deemed to have been received by the addressee where
the notice or other document is sent by overnight courier, by hand or is given by facsimile, simultaneously with the delivery. 
 10.2
Entire Agreement; Amendment. 
 (a) This Agreement, together with the Technical
Agreement to be entered into pursuant to the terms hereof, the Product Acquisition Agreement and the Exhibits and Schedules attached hereto and thereto, embodies and sets forth the entire agreement and understanding of the parties with respect to
the subject matter herein and there are no promises, terms, conditions or obligations, oral or written, expressed or implied, other than those contained in this Agreement. The terms of this Agreements shall supersede all previous oral or written
agreements which may exist or have existed between the parties relating to the subject matter of this Agreement. No party shall be entitled to rely on any agreement, understanding or arrangement which is not expressly set forth in this Agreement.
Any other terms and conditions, including without limitation any terms and: conditions contained in any purchase order or sales invoice issued
pursuant to this Agreement, are hereby expressly excluded. 
 (b) This Agreement shall not be amended, modified, or supplemented except in
writing signed by duly authorized representatives of the parties. 
 10.3 Force Majeure/Failure to Supply. If a party is prevented or
delayed in the performance of any of its obligations under this Agreement by Force Majeure arid shall give written notice thereof to the other party specifying the matter(s) constituting Force Majeure together with such evidence as such party
reasonably can give and specifying the period for which it is estimated that such 

  

 - 22 - 

 
prevention or delay will continue, the party shall be excused from the performance or the punctual performance of such obligations as the case may be from
the date of such notice for so long as such cause of prevention or delay shall continue. The expression “Force Majeure” shall be deemed to include circumstances or events, which cannot be avoided nor prevented by applying due care
and economically appropriate means, in particular acts of God, war, hostilities, terrorism, riot, fire, explosion, accident, flood, sabotage, lack of adequate fuel, power, raw materials, containers, transportation or labor, strike, lock-out or
injunction (provided that neither Party to this Agreement shall be required to settle a labor dispute against its own best judgment), compliance with governmental Laws, regulations or orders, breakage or failure of machinery or apparatus, and which
significantly impair or aggravate the performance of this Agreement. 
 10.4 Assignment. Subject to the provisions of Section 2.9
hereof, neither party hereto shall be entitled to assign its rights arid obligations hereunder without the prior written consent of the other party; provided, however, (i) each party shall be entitled, without the prior written
consent of the other party, to assign its rights and obligations hereunder to an Affiliate, but such assignment to an Affiliate shall not relieve the assigning party of its obligations hereunder, (ii) Aventis shall be entitled, without the
prior written consent of Purchaser, to assign its rights and obligations hereunder, in whole or in part, to any acquirer of the business or any material assets utilized in the manufacture of Product, so long as such acquirer of such business or
assets assumes in writing Aventis’ obligations hereunder, and (iii) Aventis shall not unreasonably withhold, condition or delay its consent to assignment in connection with a sale by Purchaser of its ownership rights in any of the
Products, including, without limitation, any Product Registrations. No permitted assignment hereunder shall be deemed effective until the assignee shall have executed and delivered an instrument in writing reasonably satisfactory in form and
substance to the other party pursuant to which the assignee assumes all of the obligations of the assigning party hereunder. Any purported assignment of this Agreement in violation of this Section 10.4 shall be void. This Agreement shall be
binding upon the successors and permitted assigns of the parties and the name of a party shall be deemed to include the names of its successors and assigns. 
 10.5 Headings, Interpretation. The headings used in this Agreement are for convenience only and are not a part of this Agreement nor affect the interpretation of any of its provisions. 
 10.6 Independent Parties. This Agreement shall not be deemed to create any partnership, joint venture, amalgamation or agency relationship between
Aventis and Purchaser. Each party shall act hereunder as an independent contractor. 
 10.7 Governing Law. This Agreement shall be
governed by and construed under the laws of the State of New York, without giving effect to the choice of law provisions thereof. 
 10.8
No Waiver. Neither the failure nor delay on the part of a party to require the strict performance of any term, covenant or condition of this Agreement or to exercise any right or remedy available on a breach thereof shall constitute a waiver
of any such breach or of any such term or condition. The consent to, or the waiver of, any breach, or the failure to require on any single occasion 

  

 - 23 - 

 
the performance or timely performance of any term, covenant, or condition of this Agreement shall not be construed as authorizing any subsequent or
additional breach and shall not prevent a subsequent enforcement of such term, covenant, or condition. 
 10.9 Severability. In the
event that any provision of this Agreement or the application thereof to any party or circumstance shall be finally determined by a court of proper jurisdiction to be invalid or unenforceable to any extent, then (i) a suitable and equitable
provision shall be substituted therefore in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid and unenforceable provision, and (ii) the remainder of this Agreement and the application of such
provision to the parties or circumstances other than those to which it is held invalid or unenforceable shall not be affected thereby. 
 10.10 Interpretation. The parties hereto acknowledge and agree that: (i) each party and its representatives has reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision;
(ii) the rule of construction to the effect that any ambiguities are resolved against the drafting party shall not be employed in the interpretation of this Agreement; and (iii) the terms and provisions of this Agreement shall be construed
fairly as to each party hereto and not in favor of or against either party regardless of which party was generally responsible for the preparation of this Agreement. 
 10.11 Counterparts. This Agreement may be executed simultaneously in counterparts (and may be delivered by facsimile), each of which shall be deemed an original, but all of which together shall constitute a
single agreement. 
 10.12 Third Party Beneficiaries. This Agreement is not intended to confer upon any non-party rights or remedies
hereunder, except as may be received or created as part of a valid assignment. 
 10.13 Further Assurances. Each party shall execute
and deliver such additional instruments and other documents and use commercially reasonable efforts to take or cause to be taken, all actions and to do, or cause to be done, all things necessary under Applicable Law to consummate the transactions
contemplated hereby. 
 10.14 Use of Affiliates. The rights and obligations of the parties set forth in this Agreement include the
right of each party to use its Affiliates in exercising such rights and carrying out its obligations under this Agreement; provided that in the event any such Affiliate ceases to meet the definition of an Affiliate, whether due to the transfer or
sale of all or substantially all of the assets or stock of such Affiliate or otherwise, then such right with respect to such Affiliate shall terminate. 
 10.15 Closing. Notwithstanding anything to the contrary contained herein, in the event that the Product Acquisition Agreement is terminated prior to the transactions contemplated therein being consummated and
closed, then this Agreement shall automatically terminate and be of no further force and effect. 
 10.16 Construction. The language
in all parts of this Agreement shall be construed, in all cases, according to its fair meaning. Aventis and Purchaser acknowledge that each Party and its counsel have reviewed and revised this Agreement and that any rule of construction to the
effect that any ambiguities are to be resolved against the drafting Party shall not be employed in the interpretation 

  

 - 24 - 

 
of this Agreement. Whenever used herein, the words “include,” “includes” and “including” shall mean “include, without
limitation,” “includes, without limitation” and “including, without limitation,” respectively. The masculine, feminine or neuter gender and the singular or plural number shall each be deemed to include the others whenever
the context so indicates. “Days” means calendar days unless otherwise specified. Whenever used herein, the words “Aventis” and “Purchaser” shall mean also their respective Affiliates whenever the context shall require
or to the extent applicable. 
 [Signatures on Following Page] 
  

 - 25 - 

 IN WITNESS WHEREOF, the Parties hereto have each caused this Agreement to be duly executed in the United
States, as of the date first above written. 
  

			
	AVENTIS:
	
	AVENTIS PHARMACEUTICALS INC.
		
	By:	 	 /s/ Juergen Lasowski

	Name:	 	Juergen Lasowski
	Title:	 	Vice President, Business Development & Strategy, North America
	
	Authorized Signatory for Aventis Pharmaceuticals Inc.

 SIGNATURE PAGE TO CARAFATE® SUPPLY AGREEMENT 

 IN WITNESS WHEREOF, the Parties hereto have each caused this Agreement to be duly executed in the United
States, as of the date first above written. 
  

			
	PURCHASER:
	
	AXCAN PHARMA INC.
		
	By:	 	 /s/ Léon F. Gosselin

	Name:	 	Léon F. Gosselin
	Title:	 	President and Chief Executive Officer

 SIGNATURE PAGE TO CARAFATE® SUPPLY AGREEMENT 

 SCHEDULED FIRM ORDERS FOR FIRST 4 MONTHS 
  

											
	 LMID/GMID
	  	 Product
 Description
	  	 November
Production
 Plan
	  	 December
Production
 Plan
	  	 January
 Production
 Plan
	  	 February
Production
 Plan

	[ ** ]	  	Carafate Susp*	  	[ ** ]	  	[ ** ]	  	 0
	  	 0

	[ ** ]	  	Carafate Tabs 3000 ct	  	[ ** ]	  	[ ** ]	  	[ ** ]	  	[ ** ]
	[ ** ]	  	Carafate Tabs 100 ct	  	[ ** ]	  	[ ** ]	  	[ ** ]	  	[ ** ]
	[ ** ]	  	Carafate Tabs 120 ct	  	[ ** ]	  	[ ** ]	  	[ ** ]	  	[ ** ]
	[ ** ]	  	Carafate Tabs 500 ct	  	[ ** ]	  	[ ** ]	  	[ ** ]	  	[ ** ]

  

	 *
	 The production plan for March and April with respect to the Carafate ® Suspension Product shall also be zero. 

 SCHEDULE 2.6 
 PRODUCT QUANTITIES/CAPACITY ANALYSIS 
  

									
	 Product
	  	 Minimum Order
 Quantity
	  	 Batch Equivalent
 Per Minimum
 Order
	  	 Monthly
 Capacity
	  	 Annual
 Capacity

	 Carafate®/Sucralfate Tablet
	  	[ ** ] tablets	  	[ ** ] Batch	  	[ ** ] Batches	  	[ ** ] Batches
	 Carafate® Suspension
	  	[ ** ] bottles	  	[ ** ] Batch	  	[ ** ] Batches	  	[ ** ] Batches

  

 - 3 - 

 SCHEDULE 3.1 
 INITIAL PRODUCT COSTS 
 A. The following prices include the cost of Bulk Compound and apply so long as Aventis
is sourcing and otherwise paying for the Bulk Compound 
  

					
	 Product
	  	Price	 
	 Carafate Suspension (per bottle)
	  	$	[ 	** ]
	 Sucralfate Tablets (3000 count)
	  	$	[ 	** ]
	 Sucralfate Tablets (500 count)
	  	$	[ 	** ]
	 Sucralfate Tablets (120 count)
	  	$	[ 	** ]
	 Sucralfate Tablets (100 count)
	  	$	[ 	** ]

 The prices for the Products starting from the [ ** ] of the
Effective Date will reflect an additional automatic [ ** ]% increase over the prices ending on the day immediately preceding such [ ** ]. In addition, the prices for such contract year will be increased in accordance with the inflation adjustment as
set forth in Section 3.1(b).: The combined price increase as a result of the [ ** ]% increase and the inflation adjustment for such contract
year shall not exceed a [ ** ]% increase over the prior year’s prices. 
 The prices for the [ ** ] shall be the same as the prior year except for the
inflation adjustment set forth in Section 3.l(b). 
 B. The following prices exclude the cost of Bulk Compound and apply when Purchaser is sourcing and
otherwise paying for the Bulk Compound 
  

					
	 Product
	  	Price	 
	 Carafate Suspension (per bottle)
	  	$	[ 	** ]
	 Sucralfate Tablets (3000 count)
	  	$	[ 	** ]
	 Sucralfate Tablets (500 count)
	  	$	[ 	** ]
	 Sucralfate Tablets (120 count)
	  	$	[ 	** ]
	 Sucralfate Tablets (100 count)
	  	$	[ 	** ]

 The prices for the Products starting from the [ ** ] of the
Effective Date will reflect an additional automatic [ ** ]% increase over the prices ending on the day immediately preceding such [ ** ]. In addition, the prices for such contract year will be increased in accordance with the inflation adjustment as
set forth in Section 3.1(b).: The combined price increase as a result of the [ ** ]% increase and the inflation adjustment for such contract
year shall not exceed a [ ** ]% increase over the prior year’s prices. 
 The prices for the [ ** ] shall be the same as the prior year except for the
inflation adjustment set forth in Section 3.l(b). 
  

 - 4 - 

 [ ** ] = PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT. AN UNREDACTED VERSION OF THIS AGREEMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 AMENDMENT
NO. 1 TO THE FINISHED PRODUCT 
 SUPPLY AGREEMENT 
 This Amendment No. 1 to the Finished Product Supply Agreement (this “Amendment”) is entered into as of August 2, 2008 (the “Amendment Date”), by and between:

  

			
		 	 SANOFI-AVENTIS U.S. LLC, a limited liability company organized and existing under the laws of Delaware, with an office located at 10236
Marion Park Drive, Kansas City, Missouri, USA 64137-1405 (“Sanofi”);
  
 and
  
 AXCAN PHARMA INC., a corporation organized and existing under the
laws of Canada, with its principal office located at 597 Laurier Boulevard, Mont-Saint-Hilaire, Quebec, Canada, J3H 6C4, on behalf of itself and its Affiliates (“Axcan Pharma” or the “Purchaser”);

 
 (Sanofi and Axcan may be referred to herein individually as a “Party” and
collectively as the “Parties”.)

 RECITALS 
 WHEREAS Aventis Pharmaceuticals Inc. (“Aventis”) and Axcan entered into a Finished Product Supply Agreement dated October 8, 2003 (the “Original Agreement”) with respect
to the supply of Product in the Territory; 
 WHEREAS, on or about March 2, 2006, Aventis advised Axcan by written notice that it had assigned
the Original Agreement and all rights and obligations thereunder to Sanofi; 
 WHEREAS, pursuant to section 4.1 of the Original Agreement, the term of
the Original Agreement is of five (5) years, ending on October 7, 2008 (the “Original Term”); 
 WHEREAS the Parties wish
to extend the term of the Original Agreement for an additional period of five (5) years as of the Amendment Date; 
 WHEREAS the Parties further
wish to revise and amend the Original Agreement to, amongst other things, address (i) yearly price increases, (ii) volume expansion and rebates, (iii) continuous improvement and performance evaluation, (iv) exclusivity of the
supply, and (v) necessity that the Product continue to be manufactured in its current manufacturing site; 
 NOW, THEREFORE, in consideration of
the mutual covenants and conditions herein set forth and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto hereby agree as follows: 

	1.	Amendment of Supply Terms. 

  

	 	1.1	Section 2.1 of the Original Agreement is hereby amended and restated in its entirety to read as follows: 

 “2.1 Supply and Exclusivity. Pursuant to the terms and conditions of this Agreement,
during the Term, Sanofi agrees to supply Products to Purchaser, to be manufactured from Sanofi’s manufacturing site located in Kansas City, MO. Sanofi agrees to supply the Carafate®
Suspension Product to Purchaser on an exclusive basis in the Territory, and, without limiting the foregoing, shall [ ** ] in the Territory. For purposes of this Section 2.1, [ ** ]. Nothing in this provision shall diminish the parties’
respective confidentiality obligations with respect to the Product. Sanofi shall not subcontract its obligations hereunder or change the manufacturing site for the Product without the Purchaser’s prior written consent. Purchaser agrees to
purchase, or cause to be purchased, exclusively from Sanofi or its permitted designee, Purchaser’s requirement of Products for purposes of distribution by Purchaser in the Territory. 
  

	 	1.2	Article 2 of the Original Agreement is hereby amended by the addition, after section 2.11, of the following sections 2.12 and 2.13: 

 “2.12 Service Requirements. 
  

	 	(a)	Account Management. Each of Purchaser and Sanofi will assign representatives to manage this Agreement at the following levels: 

  

	 	(i)	Account Managers: Purchaser’s Strategic Sourcing Director, Purchaser’s Strategic Sourcing Manager, Sanofi’s Director of Procurement and Sanofi’s Account Director
will monitor and implement this Agreement. Account Managers will schedule meetings to review, among other things, quality, technical, procurement and service issues. Account Managers will be accessible by phone, cell phone/pager, voice-mail and
e-mail during regular business hours. 

  

	 	(b)	Reports. Sanofi shall provide to Purchaser, at Sanofi’s costs, yearly reports containing mutually agreed pertinent business information, but shall include (i) total orders
per SKU in units and dollars, and (ii) Purchaser’s total yearly purchase. 

  

 2 

	 	(c)	Metrics and Acceptable Levels of Service. Sanofi shall use commercially reasonable efforts to provide Purchaser with a minimum of 70% overall performance (or any other target that
may be mutually agreed upon between the Parties during business reviews) (that is the total score in the “Global Evaluation” section of the “Supplier Scorecard” presented in Schedule 2.12, attached hereto), with a targeted
year-to-year level of improvement as may be agreed between the Parties from time to time, provided that failure to meet such level of performance or improvement shall not constitute a breach or violation of this Agreement.”

  

	 	“2.13	Improvement. In the either party identifies an improvement opportunity, the other party will consider such opportunity in good faith.” 

  

	2.	Amendment of the Pricing Terms. 

  

	 	2.1	Section 3.1 (b) of the Original Agreement is hereby replaced in its entirety by the following: 

 “(b) The Initial Product Costs will remain firm until [ ** ]. Beginning on [ ** ] and on [ **
] of each calendar year thereafter, the Initial Product Cost shall be increased to reflect increases in the [ ** ] for the calendar year prior to the year for which any such adjustment is to take place, provided such adjustment shall not
exceed [ ** ]% per annum (the “[ ** ] Adjustment”), provided further that, in the event Purchaser places, binding purchase orders under this Agreement during either of calendar years [ ** ] or [ ** ] for Carafate® Suspension Product in excess of [ ** ] units for delivery pursuant to this Agreement during the same calendar year, the then applicable initial Product Cost for Carafate® Suspension Product shall be increased by [ ** ]% of the [ ** ] Adjustment otherwise applicable for such year. Without limiting the generality of the foregoing, for the avoidance of doubt and
ease of administration, the parties agree that the Initial Product Cost, as adjusted by the [ ** ] Adjustment, applicable for [ ** ] to the Carafate® Suspension Product and the
Carafate® Tablet Product, is set forth on Exhibit A hereto.” 
  

	3.	Amendment of the Term Provisions. 

  

	 	3.1	Section 4.1 of the Original Agreement is hereby amended and restated in its entirety to read as follows: 

 “4.1 Term. The Term will commence upon the Effective Date and will continue until August 1, 2013, unless terminated earlier in accordance
with the provisions of Section 4.2 (the “Term”). Twelve (12) months prior to the end of this initial Term, in the event that this Agreement has not been previously terminated and Purchaser is not in material default
hereunder (but solely to the extent Sanofi has provided prior written notice of such material default to Purchaser), the Agreement shall be automatically renewed for an additional three (3) year period after the end of the initial Term, unless
Purchaser has sent a prior written notice of not less than twelve (12) months advising Sanofi of its decision not to renew the Agreement. If the Agreement is renewed, the Term shall be deemed to include such additional period.” 

 

 3 

	 	3.2	Section 4.2(d) of the Original Agreement shall be amended and restated in its entirety as follows: 

 “(d) after the third anniversary of the Amendment Date, Purchaser may provide not less than twelve (12) months prior written notice to Aventis
of its election to terminate (e.g., the earliest the Agreement could be terminated would be the fourth anniversary of the Amendment Date); or” 
  

	4.	Amendment of the Schedules. 

  

	 	4.1	The Agreement is hereby amended by the addition of Schedule 2.12, “Supplier Scorecard”, attached hereto as Exhibit B. 

  

	 	4.2	Schedule 3.1 is hereby amended by the deletion, in each of sections A and B, of the two last paragraphs. 

  

	5.	Miscellaneous. 

  

	5.1	Any term beginning with an uppercase letter herein that is not otherwise defined in this Amendment shall have meaning ascribed to it in the Original Agreement, unless the context
dictates otherwise. 

  

	5.2	The titles to the articles or sections in this Amendment are not part of this Amendment or the Agreement and are included merely for convenience of reference only and shall not
affect its meaning or interpretation. 

  

	5.3	Except as specifically provided for in this Amendment, the terms and conditions of the Agreement remain unchanged and in full force and effect, and are hereby confirmed.

  

	5.4	This Amendment may be signed in any number of counterparts with the same effect as if the signatures thereto were upon the same instrument. 

 [Signatures on next page] 
  

 4 

 IN WITNESS WHEREOF, the Parties hereto have caused this Amendment to be executed by their duly authorized officers
with effect as of the date set forth hereinabove. 
  

									
	AXCAN PHARMA INC.	 		 	SANOFI-AVENTIS U.S. LLC
					
	By:	 	 /s/ Frank AGM Verwiel
	 		 	By:	 	 /s/ Osric Reavis

	Name:	 	Frank AGM Verwiel	 		 	Name:	 	Osric Reavis
	Title:	 	President and CEO	 		 	Title:	 	Vice President
	Date:	 	July 31, 2008	 		 		 	U.S. Industrial Affairs
		 		 		 	Date:	 	8/20/08
					
		 		 		 	By:	 	 /s/ Laurent Gilhodes

		 		 		 	Name:	 	LAURENT GILHODES
		 		 		 	Title:	 	Vice President & Chief Financial Officer
		 		 		 	Date:	 	8/28/08

  

 5 

 EXHIBIT A 
 2007 Adjusted Initial Product Cost 
  

					
	 Product
	  	 Unit
	  	Cost
	Carafate Suspension	  	16 oz bottle	  	$ [ ** ]
	Carafate Tablet	  	100ct bottle	  	$ [ ** ]

  

 6 

 EXHIBIT B 
 Supplier Scorecard 
  

 7 

 SUPPLIER SCORECARD 
 [ ** ]Manufacturing Services Agreement between Patheon Inc. and Axcan Pharma Inc.

 Exhibit 10.7 
 [ ** ] = PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. AN UNREDACTED VERSION OF THIS AGREEMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 Manufacturing Services Agreement 
 between 
 PATHEON INC. 
 and 
 AXCAN PHARMA INC.

 October 1, 2003 

 TABLE OF CONTENTS 
  

							
	 ARTICLE 1 - INTERPRETATION
	  	1
				
		 	 1.1
	  	 Definitions
	  	1
		 	 1.2
	  	 Currency
	  	4
		 	 1.3
	  	 Sections and Headings
	  	4
		 	 1.4
	  	 Singular Terms
	  	4
		 	 1.5
	  	 Schedules
	  	4
		
	 ARTICLE 2 - PATHEON’S OBLIGATIONS
	  	4
				
		 	 2.1
	  	 Manufacturing Services
	  	4
		 	 2.2
	  	 Standard of Performance
	  	7
		
	 ARTICLE 3 - CLIENT’S OBLIGATIONS
	  	7
				
		 	 3.1
	  	 Payment
	  	7
		 	 3.2
	  	 Active Pharmaceutical Ingredient
	  	7
		 	 3.3
	  	 API and Finished Product Testing
	  	7
		 	 3.4
	  	 Axcan Affiliates
	  	8
		
	 ARTICLE 4 - CONVERSION FEES AND COMPONENT COSTS
	  	8
				
		 	 4.1
	  	 Fees and Component Costs
	  	8
		 	 4.2
	  	 Subsequent Years’ Pricing
	  	8
		 	 4.3
	  	 Adjustments to Pricing
	  	9
		 	 4.4
	  	 Adjustments Due to Technical Changes
	  	10
		 	 4.5
	  	 Multi-Country Packaging Requirements
	  	10
		
	 ARTICLE 5 - ORDERS, DELIVERY, INVOICING, PAYMENT, PRODUCT DEFICIENCIES
	  	11
				
		 	 5.1
	  	 Orders and Forecasts
	  	11
		 	 5.2
	  	 Reliance by Patheon
	  	11
		 	 5.3
	  	 Minimum Orders
	  	12
		 	 5.4
	  	 Shipments
	  	12
		 	 5.5
	  	 Invoices and Payment
	  	12
		 	 5.6
	  	 Product Deficiencies
	  	13
		
	 ARTICLE 6 - CO-OPERATION
	  	13
				
		 	 6.1
	  	 Review
	  	13
		 	 6.2
	  	 Product Recalls and Returns
	  	14
		 	 6.3
	  	 Customer Questions and Complaints
	  	14
		 	 6.4
	  	 Records and Accounting by Patheon
	  	15
		 	 6.5
	  	 Inspection
	  	15
		 	 6.6
	  	 Access
	  	15
		 	 6.7
	  	 FDA Filings
	  	15

  

 - i - 

							
	 ARTICLE 7 - TERM AND TERMINATION
	  	16
				
		  	7.1	  	 Initial Term
	  	16
		  	7.2	  	 Termination for Cause
	  	16
		  	7.3	  	 Product Discontinuation
	  	17
		  	7.4	  	 Obligations on Termination
	  	17
		
	 ARTICLE 8 - REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	18
				
		  	8.1	  	 Authority
	  	18
		  	8.2	  	 Non-Infringement
	  	18
		  	8.3	  	 Permits
	  	18
		  	8.4	  	 Compliance with Laws
	  	19
		  	8.5	  	 No Warranty
	  	19
		
	 ARTICLE 9 - REMEDIES AND INDEMNITIES
	  	19
				
		  	9.1	  	 Consequential Damages
	  	19
		  	9.2	  	 Limitation of Liability
	  	19
		  	9.3	  	 Patheon
	  	20
		  	9.4	  	 Client
	  	20
		
	 ARTICLE 10 - CONFIDENTIALITY
	  	21
				
		  	10.1	  	 Confidentiality
	  	21
		
	 ARTICLE 11 - DISPUTE RESOLUTION
	  	21
				
		  	11.1	  	 Commercial Disputes
	  	21
		  	11.2	  	 Technical Dispute Resolution
	  	21
		
	 ARTICLE 12 - MISCELLANEOUS
	  	22
				
		  	12.1	  	 Intellectual Property
	  	22
		  	12.2	  	 Insurance
	  	22
		  	12.3	  	 Independent Contractors
	  	22
		  	12.4	  	 No Waiver
	  	23
		  	12.5	  	 Assignment
	  	23
		  	12.6	  	 Force Majeure
	  	23
		  	12.7	  	 Additional Product
	  	23
		  	12.8	  	 Notices
	  	23
		  	12.9	  	 Severability
	  	24
		  	12.10	  	 Entire Agreement
	  	24
		  	12.11	  	 No Third Party Benefit or Right
	  	25
		  	12.12	  	 Execution in Counterparts
	  	25
		  	12.13	  	 Governing Law
	  	25

  

 - ii - 

 MANUFACTURING SERVICES AGREEMENT 
 THIS MANUFACTURING SERVICES AGREEMENT (the “Agreement”) dated the
     day of November, 2004 with effect as of the 1st day of October, 2003 
 BETWEEN: 

			
		  	PATHEON INC.,
		  	a corporation existing under the laws of Canada,
		
		  	(hereinafter referred to as “Patheon”),
		
		  	 - and -

		
		  	AXCAN PHARMA INC.
		  	a corporation existing under the laws of Canada,
		
		  	(hereinafter referred to as the “Client”).

 THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations
assumed herein, and for other good and valuable consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound the parties agree as follows: 
 ARTICLE 1 - INTERPRETATION 
  

	1.1	Definitions. 

 The following terms shall,
unless the context otherwise requires, have the respective meanings set out below and grammatical variations of such terms shall have corresponding meanings: 
 “Active Pharmaceutical Ingredient” or “API” means the materials listed on Schedule B hereto; 
 “Affiliate” means: 
  

	 	(a)	a business entity which owns, directly or indirectly, a controlling interest in a party to this Agreement, by stock ownership or otherwise; or 

  

	 	(b)	a business entity which is owned by a party to this Agreement, either directly or indirectly, by stock ownership or otherwise; or 

  

	 	(c)	a business entity, the majority ownership of which is directly or indirectly common to the majority ownership of a party to this Agreement; 

 “API Value” has the meaning specified in Section 9.2(a); 
  

 - 1 - 

 “Business Day” means a day other than a Saturday, Sunday or a day that is a statutory
holiday in the province of Ontario or the province of Québec, Canada; 
 “cGMPs” means current Good Manufacturing
Practices as described in: 
  

	 	(a)	Division 2 of Part C of the Food and Drug Regulations (Canada); and 

  

	 	(b)	Parts 210 and 211 of Title 21 of the United States Code of Federal Regulations, 

 together with the latest Health Canada and FDA guidance documents pertaining to manufacturing and quality control practice, all as updated, amended and revised from time to time; 
 “Components” means, collectively, all packaging components, raw materials and ingredients (including labels, product inserts and other
labelling for the Products), required to be used in order to produce the Products in accordance with the Specifications, other than the Active Pharmaceutical Ingredient; 
 “Confidentiality Agreement” means the agreement relating to the non-disclosure of confidential information between Patheon and the Client dated January 11, 2002; 
 “Deficiency Notice” shall have the meaning ascribed thereto in Section 5.6(a); 
 “Effective Date” means the date first hereinabove mentioned; 
 “EXW” means “Ex works”, as that term is defined in INCOTERMS 2000; 
 “Facility” means the manufacturing facility of Patheon, located at 865 York Mills Road, Toronto, Ontario, M3B 1Y5 where manufacturing of
the Products under this Agreement shall take place; 
 “FDA” means the United States government department known as the Food
and Drug Administration; 
 “Firm Orders” has the meaning specified in Section 5.1(b); 
 “Health Canada” means the section of the Canadian government known as Health Canada and includes, among other departments, the
Therapeutic Products Directorate and the Health Products and Food Branch Inspectorate; 
 “Intellectual Property” includes,
without limitation, rights in patents, patent applications, formulae, trade-marks, trade-mark applications, trade-names, trade secrets, inventions, copyright, industrial designs, know-how; 
 “Inventory” means all inventories of Components and work-in-process produced or held by Patheon in connection with the manufacture of the
Products but, for greater certainty, does not include the Active Pharmaceutical Ingredient; 
  

 - 2 - 

 “Manufacturing Services” means the manufacturing, quality control, quality assurance
testing, packaging and related services, as contemplated in this Agreement, required to produce Products from Active Pharmaceutical Ingredient and Components; 
 “Manufacturing Requirements” means Patheon’s responsibilities and obligations with respect to the provision of Manufacturing Services as set forth in Article 2; 
 “Maximum API Value” has the meaning specified in Section 9.2(a); 
 “Minimum Run Quantity” means the minimum quantity of a Product, expressed in packaged units, to be produced during the same cycle of
manufacturing as set forth in Schedule A hereto; 
 “Products” means the products listed on Schedule A hereto; 
 “Quality Agreement” means the agreement to be entered into between Patheon and the Client setting out the quality assurance standards to
be applicable to the Manufacturing Services provided by Patheon, which agreement shall be substantially in the form of the agreement attached hereto as Schedule D; 
 “Specifications” means the file, for each Product, which is provided by the Client to Patheon, including, without limitation, the documents attached hereto as Schedule F, and which contains documents
relating to such Product, including, without limitation: 
  

	 	(a)	written specifications for Active Pharmaceutical Ingredient, Components and finished Product; 

  

	 	(b)	manufacturing and packaging specifications; 

  

	 	(c)	shipping and storage requirements; 

  

	 	(d)	all environmental, health and safety information relating to the Product, including material safety data sheets, all as updated, amended and revised from time to time by the Client
in accordance with the terms of the Agreement; and 

  

	 	(e)	any other technical information necessary to carry out the contracted operations correctly in accordance with the marketing authorisation and any other legal requirements,

 all as updated, amended and revised from time to time by the Client in accordance with the terms of this Agreement;

 “Technical Dispute” has the meaning specified in Section 11.2; 
 “Territory” means the geographic area of the United States and Canada; 
 “Third Party Rights” means the Intellectual Property of any third party; 
  

 - 3 - 

 “Year” means the twelve-month period commencing, in the case of the first Year of this
Agreement, on the Effective Date, and thereafter commencing upon completion of the immediately preceding Year. 
  

	1.2	Currency. 

 Unless otherwise indicated, all
monetary amounts are expressed in this Agreement in the lawful currency of Canada. 
  

	1.3	Sections and Headings. 

 The division of this
Agreement into Articles, sections, subsections and Schedules and the insertion of headings are for convenience of reference only and shall not affect the interpretation of this Agreement. Unless otherwise indicated, any reference in this Agreement
to a Section or Schedule refers to the specified Section or Schedule to this Agreement. In this Agreement, the terms “this Agreement”, “hereof, “herein”, “hereunder” and similar expressions refer to this
Agreement and not to any particular part, Section, Schedule or the provision hereof. 
  

	1.4	Singular Terms. 

 Except as otherwise
expressly provided herein or unless the context otherwise requires, all references to the singular shall include the plural and vice versa. 
  

	1.5	Schedules. 

 The following Schedules are
attached to, incorporated in and form part of this Agreement: 
  

					
	Schedule A	  	–	  	Product, Minimum Run Quantity, Estimated Annual Volume, Target Yield and Fees
	Schedule B	  	–	  	Active Pharmaceutical Ingredient & Value
	Schedule C	  	–	  	Technical Dispute Resolution
	Schedule D	  	–	  	Quality Agreement
	Schedule E	  	–	  	Batch Numbering and Expiration Dates
	Schedule F	  	–	  	Finished Product Specifications
	Schedule G	  	–	  	Logistics Routing Guide
	Schedule H	  	–	  	Component Liability

 ARTICLE 2 - PATHEON’S OBLIGATIONS 
  

	2.1	Manufacturing Services. 

 Patheon shall
provide the Manufacturing Services for the Territory for the fees specified in Schedule A in order to produce Products for the Client. The Client shall purchase its entire requirement of Products for sale in the Territory from Patheon pursuant to
the terms of this Agreement. Notwithstanding the foregoing, Patheon hereby acknowledges that the Client may purchase up to [ ** ] of its requirement of Products from another manufacturer. In providing the Manufacturing Services: 
  

	 	(a)	Conversion of Active Pharmaceutical Ingredient and Components. 

  

 - 4 - 

	 	(i)	Patheon shall convert Active Pharmaceutical Ingredient and Components into Products. Patheon shall provide the Client with a quarterly inventory report and reconciliation of the API
held by Patheon, which shall contain the following information for such quarter: 

 Quantity Received means the total
quantity of API that complies with the Specifications received at the Facility during the applicable period. 
 Quantity Dispensed
means the total quantity of API dispensed at the Facility during the applicable period. The Quantity Dispensed is calculated by adding the Quantity Received to the inventory of API that complies with the Specifications held at the beginning of the
applicable period, less the inventory of API that complies with the Specifications held at the end of such period. The Quantity Dispensed shall only include API received and dispensed in connection with commercial manufacturing of Products and, for
certainty, shall not include any API received or dispensed in connection with technical transfer activities or development activities during the applicable period, including, without limitation, any regulatory, stability, validation or test batches
manufactured during the applicable period. 
 Quantity Converted means the total amount of API contained in the Products produced with
the Quantity Dispensed, delivered by Patheon, and not rejected, recalled or returned as a result of a failure of Patheon to provide Manufacturing Services in accordance with the Manufacturing Requirements. 
 Patheon shall calculate the yield for each Product for each applicable period, to be calculated by dividing, for each Product, the Quantity Converted by
the Quantity Dispensed (each, an “Actual Yield”). The Actual yield shall be greater than or equal to the Target Yield set out in Schedule A. Based upon historical Actual Yield data supplied by Patheon, the parties have agreed to set
the target Yield levels for each Product (each a “Target Yield”) set out in Schedule A. Patheon hereby undertakes to strive to maintain Yield levels for each Product to the process and meet the agreed Target Yield. This will be
reviewed and discussed at the business review meetings. 
  

	 	(ii)	Whenever Patheon agrees to manufacture another product or a new stock keeping unit (“SKU”) is created, Patheon shall collect Yield data from the first ten
(10) batches of such product or SKU. Once this data has been collected, the parties will agree on a specific Target Yield for such product or SKU. Patheon hereby undertakes to strive to aim for a ninety percent (90%) Yield for each such
new product or SKU. 

  

 - 5 - 

	 	(b)	Quality Control and Quality Assurance. Patheon shall perform the quality control and quality assurance testing specified in the Quality Agreement. For certainty, the Client
acknowledges that all finished Product testing is performed by Client’s third party laboratory. As a result, Patheon shall not be responsible for finished Product testing or for supplying certificates of analysis in respect of such finished
Products; 

  

	 	(c)	Components. Patheon shall purchase all Components and test all Components at Patheon’s expense as specified by the Specifications. 

  

	 	(d)	Active Pharmaceutical Ingredients. API will be tested by Client’s third party laboratory prior to delivery to Patheon. Upon delivery of the API at the Facility, Patheon
shall rely on the certificate of analysis that is supplied with the incoming API and shall only conduct identity testing on such API. To the extent that Patheon discovers defective API during such review, Patheon shall promptly give the Client
written notice of any API that are not in compliance with the Specifications. 

 Patheon’s liability with
respect to any lost or damaged API shall be as set forth in Section 9.2. 
  

	 	(e)	Packaging. Patheon shall package the Product with labels, product inserts and other packaging as set out in the Specifications. In addition, Patheon shall make arrangements
for and implement the imprinting of batch numbers and expiration dates for each Product shipped. Such batch numbers and expiration dates shall be affixed on the Product and on the shipping carton of the Product as outlined in the Specifications and
as required by cGMPs. The system used by Patheon for batch numbering and expiration dates is detailed in Schedule E hereto. The Client may, in its sole discretion, make changes to labels, product inserts and other packaging for the Product, which
changes shall be submitted by the Client to all applicable governmental agencies and other third parties responsible for the approval of the Product. Patheon’s name shall not appear on the label or anywhere else on the Product unless required
by a governmental authority or applicable laws or regulations. 

  

	 	(f)	API Importing. Patheon and the Client will cooperate and provide such assistance and information to each other as may be reasonably necessary to permit the import of the API
into Canada. Each party shall ensure that the information provided in connection with this Section 2.1(f) is accurate and shall bear any costs, expenses and damages (including, without limitation, any fines and penalties) which the other party
may incur as a result of the inaccuracy of such information. 

  

 - 6 - 

	2.2	Standard of Performance. 

 Patheon shall
provide the Manufacturing Services in accordance with (i) the provisions of Article 2 hereof; (ii) the Specifications and cGMPs; and (iii) any other terms and conditions provided in the Quality Agreement (hereinafter collectively the
“Manufacturing Requirements”). 
 ARTICLE 3 - CLIENT’S OBLIGATIONS 
  

	3.1	Payment. 

 Pursuant to the terms of this
Agreement, the Client shall pay Patheon for the provision of the Manufacturing Services according to the fees specified in Schedule A hereto (such fees being subject to adjustment in accordance with the terms hereof). 
  

	3.2	Active Pharmaceutical Ingredient. 

 The
Client shall, at its sole cost and expense, deliver the API to Patheon in sufficient quantities to meet each Firm Order not later than the date of submission of the relevant Firm Order pursuant to Section 5.1(b), which API shall be held by
Patheon on behalf of the Client on the terms and subject to the conditions herein contained. 
 Client’s failure to supply Patheon with
API in accordance with the timeframes set forth in this Section 3.2 shall not be deemed a breach of this Agreement but shall release Patheon from strict compliance with the Delivery Date(s) specified in a particular Firm Order, provided
however, Patheon shall use all commercially reasonable efforts to meet the Delivery Dates specified in a Firm Order once the Client supplies Patheon with API. 
 The parties acknowledge and agree that title to the API shall at all times belong to and remain the property of the Client. Patheon agrees that any API received by it shall only be used by Patheon to provide the
Manufacturing Services. Patheon’s liability with respect to any lost or damaged Active Pharmaceutical Ingredient shall be as set forth in Section 9.2. 
  

	3.3	API and Finished Product Testing. 

 The
parties acknowledge that the Client has engaged a third party laboratory to provide API and finished Product testing, at the Client’s expense. The Client shall ensure that API is delivered to Patheon with a certificate of analysis certifying
that the API complies with the Specifications. 
 In the event the Client makes a claim hereunder with respect to defective Product, the
Client shall, upon Patheon’s written request, transfer the Product test methods to Patheon or to a mutually agreed third party for independent testing and analysis. The costs incurred to transfer and validate the test method (including any
further development required for validation) and to perform the evaluation shall be borne by Patheon if the claim is found to arise from Patheon’s failure to provide the Manufacturing Services in accordance with the Manufacturing Requirements,
otherwise such costs shall be borne by the Client. 
  

 - 7 - 

	3.4	Axcan Affiliates. 

 Any obligation of Axcan
under or pursuant to this Agreement may be satisfied, met or fulfilled, in whole or in part, at Axcan’s sole and exclusive option, either by Axcan directly or by any affiliate of Axcan that Axcan causes to satisfy, meet or fulfill such
obligation, in whole or in part. 
 ARTICLE 4 - CONVERSION FEES AND COMPONENT COSTS 
  

	4.1	Fees and Component Costs. 

 The fees for the
Manufacturing Services (which fees include Component Costs) listed in Schedule A are intended by the parties to be fixed for the first Year of this Agreement, subject to any amendments to such fees in accordance with Section 4.3 hereof.

  

	4.2	Subsequent Years’ Pricing. 

 The fees for the
Manufacturing Services provided pursuant to the terms of this Agreement during any period following the first anniversary of this Agreement shall be determined in accordance with the following: 
  

	 	(a)	Manufacturing Costs. On [ ** ] of each Year of this Agreement, Patheon shall be entitled to an adjustment to the fees for (i) Manufacturing Services in respect of the
Products to reflect inflation, which adjustment shall be based on the increase in the [ ** ] of the then current Year compared to the same month of the preceding Year, unless the parties otherwise agree in writing; and (ii) Component costs to
pass on the [ ** ]. In addition to the foregoing, Patheon shall also have the right on each of the [ ** ] of this Agreement to increase the fees for the Manufacturing Services in respect of the [ ** ] product to reflect [ ** ], provided that such
additional increase shall not exceed [ ** ]% or the previous Year’s fees. 

  

	 	(b)	Annual Forecast. At least two hundred ten (210) days prior to the end of each Year of this Agreement, the Client shall provide Patheon a yearly volume projection. To the
extent that Patheon determines that the projections contained in that yearly volume forecast necessitate that an adjustment be made to the Manufacturing Services fees in respect of any Product for such Year, Patheon shall, within thirty
(30) days of receipt by Patheon of the yearly forecast, be entitled to request an appropriate price adjustment, to be agreed upon by the parties. 

  

	 	(c)	 Pricing Basis. The Client acknowledges that the fee for Manufacturing Services in respect of a Product in any Year is quoted based upon the Minimum Run
Quantity for such Product specified in Schedule A and is subject to change if the 

  

 - 8 - 

	 	 
specified Minimum Run Quantity is not met. For greater certainty, if Patheon and the Client agree that the Minimum Run Quantity in respect of a Product shall
be reduced and, as a result of such reduction, Patheon’s fees for services relating to such Product increase on a per unit basis, then Patheon shall be entitled to an increase in the fee for Manufacturing Services in respect of such Product, as
provided in Section 4.3(a) herein below. 

 In connection with a fee adjustment pursuant to Section 4.2(a), Patheon shall deliver
to the Client a revised Schedule A and a statement outlining the percentage increase in the [ ** ] upon which such fee adjustment is based. In connection with all fee adjustment requests pursuant to this Section 4.2(b) and 4.2(c), Patheon shall
deliver to the Client a revised Schedule A and such budgetary pricing information or other documentation reasonably sufficient to demonstrate that a fee adjustment is justified, provided that Patheon shall have no obligation to provide any
supporting documents to the extent such documents are subject to obligations of confidentiality between Patheon and its suppliers. Patheon shall deliver such fee adjustment requests to Client for review and approval on or before [ ** ] of each Year.
Upon delivery of such a request, each of the Client and Patheon shall forthwith use all reasonable efforts to agree on a revised fee for the Manufacturing Services in respect of each affected Product. Adjustments to the fees for Manufacturing
Services pursuant to this Section 4.2 shall be effective with respect to all orders shipped on or after [ ** ] of each Year. 
  

	4.3	Adjustments to Pricing. 

 During any Year of this Agreement,
the fees set out in Schedule A shall be subject to adjustment in accordance with the following: 
  

	 	(a)	Volume Reduction. If Firm Orders for a Product amount to less than the Minimum Run Quantity for such Product, as set out in Schedule A, then Patheon shall be entitled to
request an adjustment to the fee for Manufacturing Services in respect of that Product to reflect the increased costs that Patheon will incur as a result of the reduced run quantity. To the extent that the fee for Manufacturing Services in respect
of a Product has been previously adjusted pursuant to this clause (a) to reflect its reduced run quantity, the adjustment provided in this clause (a) shall operate based on the fees attributed to such Product at the time the last of such
adjustments were made. 

  

	 	(b)	 Extraordinary Increases in Component Costs. If at any time market conditions result in Patheon’s cost of Components being materially greater than normal
forecasted increases, then Patheon shall be entitled to request an adjustment to the fee for Manufacturing Services in respect of any affected Product to compensate it for such increased Component costs. For the purposes of this Section 4.3(b),
changes materially greater than normal forecasted increases shall be considered to have occurred if: (i) the cost of a Component increases by [ ** ]% of the cost for that Component upon which the fee quote was based; or (ii) the aggregate
cost for all Components required to manufacture a Product increases by [ ** ]% of the total Component costs for such Product upon which the fee quote was based. To the extent that Manufacturing Services 

  

 - 9 - 

	 	 
fees have been previously adjusted pursuant to Section 4.2(a) or this Section 4.3(b) to reflect an increase in the cost of one or more Components,
the adjustments provided for in (i) and (ii) above shall operate based on the costs attributed to such Component (or Components) at the time the last of such adjustments were made. 

 In connection with a fee adjustment request pursuant to this Section 4.3, Patheon shall deliver to the Client a revised Schedule A and such budgetary pricing
information, adjusted Component costs or other documentation reasonably sufficient to demonstrate that a fee adjustment is justified, provided that Patheon shall have no obligation to provide any supporting documents to the extent such documents are
subject to obligations of confidentiality between Patheon and its suppliers. Upon delivery of such a request, each of the Client and Patheon shall forthwith use all reasonable efforts to agree on a revised fee for the Manufacturing Services in
respect of each affected Product. 
  

	4.4	Adjustments Due to Technical Changes. 

 Amendments to the Specifications or the Quality Agreement requested by the Client will only be implemented following a technical and cost review by Patheon and are subject to the Client and Patheon reaching agreement as to revisions, if
any, to the fees specified in Schedule A necessitated by any such amendment. If the Client accepts a proposed fee change, the proposed change in the Specifications shall be implemented, and the fee change shall become effective only with respect to
those orders of Product that are manufactured in accordance with the revised Specifications. In addition, the Client agrees to purchase, at Patheon’s cost, all Inventory utilized under the previous Specifications and purchased or maintained by
Patheon in order to fill Firm Orders or in accordance with Section 5.2, to the extent that such Inventory can no longer be utilized under the revised Specifications. Open purchase orders for Components no longer required under any revised
Specifications that were placed by Patheon with suppliers in order to fill Firm Orders or in accordance with Section 5.2 shall be cancelled where possible, and where such orders are not subject to cancellation without penalty, shall be assigned
to and satisfied by the Client. 
 Any amendments or additions to cGMPs or to applicable laws which necessitate: (a) resulting changes
to Product Specification or Manufacturing Requirements shall be conducted at the expense of the Client; and (b) resulting changes to the Facility shall be borne by Patheon. 
  

	4.5	Multi-Country Packaging Requirements. 

 If
and when the Client decides that it wishes to have Patheon manufacture the Product for countries in addition to the Territory covered by this Agreement, then the Client shall inform Patheon of the packaging requirements for each new country and
Patheon shall prepare a quotation for consideration by the Client of the additional Component costs, if any, and the change over fees for the Product destined for such new country. The agreed additional packaging requirements and related packaging
costs and change over fees shall be set out in a written amendment to this Agreement. 
  

 - 10 - 

 ARTICLE 5 - ORDERS, DELIVERY, INVOICING, PAYMENT, PRODUCT 
 DEFICIENCIES 
  

	5.1	Orders and Forecasts. 

 The Client shall
provide Patheon with the following; 
  

	 	 (a)
	 concurrent with the execution of this Agreement, a written non-binding eighteen (18) month forecast of the volume
of each Product that the Client then anticipates will be required to he produced and delivered to the Client during that eighteen (18) month period. Such forecast will be updated by the Client monthly on a rolling eighteen (18) month basis
and provided to Patheon no later than the 10th day of each month. In addition, such forecast shall be updated forthwith upon the Client determining
that the volumes contemplated in the most recent of such forecasts has changed by more than twenty per cent; and 

  

	 	(b)	on or before the 10th day of each calendar month, firm written orders (“Firm Orders”) for the Product to be produced and delivered to the Client on a date not less
than ninety (90) days from the date that the Firm Order is submitted. Such Firm Orders submitted to Patheon shall specify the Client’s purchase order number, quantities by Product type, monthly delivery schedule and any other elements
necessary to ensure the timely production and delivery of the Product. The quantities of the Product ordered in such written orders shall be firm and binding on the Client and shall not be subject to reduction; and 

  

	 	 (c)
	 Three Year Forecast. On or before March 1st in each Year, the Client shall provide Patheon with a written, non-binding three-year forecast (broken down by quarters for the second and third years of the forecast) of the volume
of each Product the Client then anticipates will be required to be produced and delivered to the Client during the three-year period. [ ** ] 

  

	5.2	Reliance by Patheon. 

 The Client understands
and acknowledges that Patheon will rely on the Firm Orders submitted pursuant to Section 5.1(b) in ordering the Components required to meet such Firm Orders. In addition, the Client understands that to ensure an orderly supply of such
Components and to achieve economies of scale in the costs, it may be desirable for Patheon to purchase such Components in sufficient volumes to meet the production requirements for Products during part or all of the forecasted periods referred to in
Section 5.1(a) or to meet the production requirements of any longer period agreed to by Patheon and the Client. Accordingly, the Client authorizes Patheon to purchase Components in order to satisfy the production requirements for Products for
the first [ ** ] months contemplated in the most recent forecast provided by the Client pursuant to Section 5.1(a), and agrees that Patheon may make such other purchases of Components to meet production requirements during such longer periods
as may be agreed to in writing from 

  

 - 11 - 

 
time to time by the Client at the request of Patheon. If Components ordered by Patheon pursuant to Firm Orders or this Section 5.2 are not included in
the finished Products purchased by the Client within six months after the forecasted month in respect of which such purchases have been made (or such longer period as the parties may agree), the Client shall pay to Patheon the cost that portion of
the Components not included in the finished Product plus the costs of all expenses incurred by Patheon for the destruction of such unused Components and, in the event such Components are incorporated into the Product subsequently purchased by the
Client, the Client will receive credit for any costs of such Components previously paid to Patheon by the Client. 
  

	5.3	Minimum Orders. 

 Subject to Section 4.3(a), the Client
may only order the Product based on the Minimum Run Quantities set out in Schedule A. 
  

	5.4	Shipments. 

  

	 	5.4.1	Shipments of the Product shall be made EXW at the Facility unless otherwise mutually agreed. Such title as Patheon has in the Product and risk of loss or of damage to the Product
shall remain with Patheon until the Product is loaded onto the carrier’s vehicle by Patheon for shipment at the Facility at which time title and risk of loss or damage shall transfer to the Client. Patheon shall, in accordance with the
Client’s instructions and as agent for the Client, (i) arrange for shipping and insurance, to be paid by the Client and (ii) at the Client’s risk and expense, obtain any export licence or other official authorization and carry
out all customs formalities necessary to export the Product. The Client may select the freight carrier used by Patheon to ship the Product and may monitor Patheon’s shipping and freight practices as they pertain to this Agreement. The Product
shall be transported in accordance with the Specifications. 

  

	 	5.4.2	Delivery dates set out in Firm Orders shall be firm and binding dates on Patheon. Notwithstanding the above provision, Patheon may arrange for the delivery of the Products five
(5) Business Days prior to the delivery date as set out in a Firm Order for such Products. Patheon shall deliver the Products two (2) Business Days prior to or past the delivery date as set out in a Firm Order (the “Delivery
Date”). 

  

	5.5	Invoices and Payment. 

 Except as otherwise
provided in this Agreement, Patheon shall charge the Client for the Manufacturing Services only in respect of those Products that are shipped to the Client and shall submit to the Client, with each shipment of Products, an invoice covering such
shipment. Each such invoice shall, to the extent applicable, identify the Client purchase order number Product numbers, names and quantities, unit price, freight charges and the total amount to be remitted by the Client. The Client shall pay all
such invoices within thirty (30) days of the date thereof. All payments to be made by cheque or by wire transfer of immediately available funds to the financial institution account number and account party’s name designated in writing by
Patheon to the Client as the place of payment. 
  

 - 12 - 

	5.6	Product Deficiencies. 

 (a)
Inspection. The Client shall inspect the Product manufactured by Patheon upon receipt thereof and, within 30 days, shall give Patheon written notice (a “Deficiency Notice”) of all claims for Products that deviate from the
Specifications or cGMPs. Should the Client fail to provide Patheon with written notice of its acceptance or rejection of the delivery within thirty (30) days of receipt of a delivery of Product, then the delivery shall be deemed to have been
accepted by the Client on the thirtieth day after delivery. Except as set out in Section 6.2, Patheon shall have no liability for any deviations for which it has not received notice within such 30-day period. 
 (b) Determination of Deficiency. Upon receipt of a Deficiency Notice, Patheon shall have 10
days to advise the Client by notice in writing that it disagrees with the contents of such Deficiency Notice. If the Client and Patheon fail to agree within ten (10) days after Patheon’s notice to the Client as to whether any Products
identified in the Deficiency Notice deviate from the Specifications or cGMPs, then the parties shall mutually select an independent laboratory to evaluate if the Product deviates from the Specifications or cGMPs. Such evaluation shall be binding on
the parties, and if such evaluation certifies that any Products deviate from the Specifications or cGMPs, the Client may reject those Products in the manner contemplated by Section 5.6(c). If such evaluation does not so certify in respect of
any such Products, then the Client shall be deemed to have accepted delivery of such Products on the fortieth (40th) day after delivery.

 (c) Product Rejection. Subject to the provisions of Sections 5.6(a) and 9.2(b), the Client has the right to reject and return, at
the expense of Patheon, any portion of any shipment of Products that deviates from the Specifications or cGMPs, without invalidating any remainder of such shipment, to the extent that such deviation arises from Patheon’s failure to provide the
Manufacturing Services in accordance with the Manufacturing Requirements. 
 (d) Shortages. Claims for shortages in the amount of
Products shipped by Patheon shall be dealt with as may reasonably be agreed to by the parties. 
 ARTICLE 6 - CO-OPERATION 

 

	6.1	Review. 

 Each party shall forthwith upon
execution of this Agreement appoint one of its employees to be a relationship manager responsible for liaison between the parties. The relationship managers shall meet not less than once a year to review the current status of the business
relationship and manage any issues that have arisen. 
  

 - 13 - 

	6.2	Product Recalls and Returns. 

 (a) Product
Recalls. Patheon and the Client shall each maintain records as may be necessary to permit a recall or a field correction of any Products delivered to the Client or customers of the Client, affected voluntarily or under a threat of, or a
directive by, any governmental agency. Each party shall give notice within one Business Day by telephone (to be confirmed in writing) to the Director of Quality Control/Quality Assurance of the other party upon discovery that any Products should be
recalled or corrected, or may be required to be recalled or corrected, and each party upon receiving any such notice or upon any such discovery, shall cease and desist from further shipments of such Products in its possession or control until a
decision has been made whether a recall or some other corrective action is necessary. The decision to initiate a recall or to take some other corrective action, if any, shall be made and implemented by the Client. Patheon will co-operate as
reasonably required by the Client, having regard to all applicable laws and regulations. 
 (b) Product Returns. The Client shall have
the responsibility for handling customer returns of the Product. Patheon shall provide the Client with such assistance as the Client may reasonably need to handle such returns. 
 (c) Patheon’s Responsibility. To the extent that a recall or return results from, or arises out of, a failure by Patheon to provide the
Manufacturing Services in accordance with the Manufacturing Requirements, such recall or return shall be made at Patheon’s cost and expense, and Patheon shall use its commercially reasonable efforts to replace the recalled or returned Products
with new Products [ ** ], contingent upon the receipt or availability from the Client of all Active Pharmaceutical Ingredient. In the event that Patheon is unable to replace the recalled Products [ ** ] (except where such inability results from a
failure to receive the required Active Pharmaceutical Ingredient), then the Client may request patheon to reimburse the Client for the price that the Client paid to Patheon for manufacturing the affected Products. In all other circumstances,
recalls, returns or other corrective actions shall be made at the Client’s cost and expense. 
  

	6.3	Customer Questions and Complaints. 

 The
Client shall have the sole responsibility for responding to questions and complaints from the Client’s customers. Questions or complaints received by Patheon from the Client’s customers shall be promptly referred to the Client. Patheon
shall co-operate as reasonably required to allow the Client to determine the cause of and resolve any customer questions and complaints. Such assistance shall include follow-up investigations, including testing. In addition, [ ** ], Patheon shall
provide the Client with all necessary information that will enable the Client to respond properly to questions or complaints relating to the Product. Unless it is determined that the cause of any customer complaint resulted from a failure by Patheon
to provide the Manufacturing Services in accordance with the Manufacturing Requirements, all costs incurred in respect of this Section 6.3 shall be borne by the Client. 
  

 - 14 - 

	6.4	Records and Accounting by Patheon. 

 Patheon
shall keep records of the manufacture, testing and shipping of the Product, and retain samples of such Product as are necessary to comply with manufacturing regulatory requirements applicable to Patheon, as well as to assist with resolving Product
complaints and other similar investigations. Copies of such records and samples shall be retained for a period of one year following the date of Product expiry, or longer if required by law. The Client is responsible for retaining samples of the
Product necessary to comply with the legal/regulatory requirements applicable to the Client. 
  

	6.5	Inspection. 

 The Client may inspect Patheon
reports and records relating to this Agreement during normal business hours and with reasonable advance written notice, provided a Patheon representative is present during any such inspection. Patheon shall promptly notify the Client of any
inspections by any governmental agency involving the Product. 
  

	6.6	Access. 

 Patheon shall provide the Client
with reasonable access at mutually agreeable times, no more than once per Year unless for cause, to any of its Facility in which the Product is manufactured, stored, handled or shipped in order to permit the Client’s verification of
Patheon’s compliance with the terms of this Agreement and with all applicable laws and regulations. For greater certainty, the right of access provided in this Section 6.6 shall not include a right to access or inspect Patheon’s
financial records. 
  

	6.7	FDA Filings. 

 (a) FDA Filings. The
Client shall have the sole responsibility for filing all documents with, the FDA and taking any other actions that may be required for the receipt of FDA Approval for the commercial manufacture of all of the Products. Patheon shall assist the
Client, to the extent consistent with Patheon’s obligations under this Agreement, to obtain FDA Approval for the commercial manufacture of all Products as quickly as reasonably possible. 
 (b) Verification of Data. At least 30 days prior to filing any documents with the FDA that incorporate data generated by Patheon, the Client shall
provide Patheon with a copy of the documents incorporating such data so as to give Patheon the opportunity to verify the accuracy and regulatory validity of such documents as they relate to the Patheon generated data. 
 (c) Verification of CMC. At least 30 days prior to filing with the FDA the Chemistry and Manufacturing Controls (“CMC”) of the
New Drug Application (“NDA”) or the Abbreviated New Drug Application (“ANDA”) filing, as the case may be, the Client shall provide Patheon with a copy of the CMC portion as well as all supporting documents which
have been relied upon to prepare the CMC portion so as to permit Patheon to verify that the CMC portion accurately describes the work that Patheon has performed and the manufacturing processes that Patheon will perform pursuant to this Agreement.

  

 - 15 - 

 (d) Pre-Approval Inspection. If Client does not provide Patheon with the documentation requested
under paragraphs (b) and (c) above within the time stipulated in these paragraphs and if Patheon reasonably believes that Patheon’s standing with the FDA may be jeopardized, Patheon may, in its sole discretion, delay or postpone the
FDA pre-approval inspection (“PAI”) until such time Patheon has reviewed the requested documentation and is satisfied with its contents. 
 (e) Deficiencies. If in Patheon’s sole discretion, acting reasonably, Patheon determines that any of the information provided by the Client in accordance with paragraphs (b) and (c) above is
inaccurate or deficient in any manner whatsoever (the “Deficiencies”), Patheon shall notify the Client in writing of such Deficiencies. Until such Deficiencies have been resolved or agreement has been reached with the Client,
Patheon reserves the right not to participate in the PAI. In such event, Patheon’s non-participation in the PAI shall not be construed as a breach of any of its obligations under this Agreement. 
 (f) Client Responsibility. For clarity, the parties agree that in reviewing the documents referred to in paragraphs (b) and (c) above,
Patheon’s role will be limited to verifying the accuracy of the description of the work undertaken or to be undertaken by Patheon. As such, Patheon shall not assume any responsibility for the accuracy of the NDA or the ANDA, as the case may be.
The sole responsibility of the preparation and filing of the NDA shall be borne by the Client. 
 ARTICLE 7 - TERM AND TERMINATION 

  

	7.1	Initial Term. 

 This Agreement shall enter
into force between the parties as of the Effective Date and shall continue for a period of five (5) years (the “Initial Term”) unless terminated earlier by one of the parties as provided herein. This Agreement shall
automatically continue after the Initial Term for successive terms of two (2) years each unless either party gives written notice to the other party of its intention to terminate this Agreement at least eighteen (18) months prior to the
end of the then current term. 
  

	7.2	Termination for Cause. 

 (a) Either party at
its sole option may terminate this Agreement upon written notice in circumstances where the other party has failed to remedy a material breach of any of its representations, warranties or other obligations under this Agreement within sixty
(60) days following receipt of a written notice (the “Remediation Period”) of said breach that expressly states that it is a notice under this Section 7.2(a) (a “Breach Notice”). The aggrieved party’s
right to terminate this Agreement pursuant to this Section 7.2(a) may only be exercised for a period of sixty (60) days following the expiry of the Remediation Period (in circumstances where the breach has not been remedied) and if the
termination right is not exercised during this period then the aggrieved party shall be deemed to have waived the breach of the representation, warranty or obligation described in the Breach Notice. 
  

 - 16 - 

 (b) Either party at its sole option may immediately terminate this Agreement upon written notice, but
without prior advance notice, to the other party in the event that (i) the other party is declared insolvent or bankrupt by a court of competent jurisdiction; (ii) a voluntary petition of bankruptcy is filed in any court of competent
jurisdiction by such other party; or (iii) this Agreement is assigned by such other party for the benefit of creditors. 
 (c) The
Client may terminate this Agreement as to any Product upon 30 days’ written notice in the event that any governmental agency takes any action, or raises any objection, that prevents the Client from importing, exporting, purchasing or selling
such Product. 
 (d) Patheon may terminate this Agreement upon six months’ prior written notice if the Client assigns pursuant to
Section 12.5 any of its rights under this Agreement to an assignee that, in the opinion of Patheon acting reasonably, is: (i) not a credit worthy substitute for the Client; or (ii) a competitor of Patheon. 
  

	7.3	Product Discontinuation. 

 The Client shall
provide at least six months’ advance notice if it intends to no longer order a Product due to that Product’s discontinuance in the market. 
  

	7.4	Obligations on Termination. 

 If this
Agreement expires or is terminated in whole or in part for any reason, then (in addition to any other remedies Patheon may have in the event of default by the Client): 
  

	 	(a)	the Client shall take delivery of and pay for all undelivered Products that are manufactured and/or packaged pursuant to a Firm Order, at the price in effect at the time the Firm
Order was placed; 

  

	 	(b)	the Client shall purchase, at Patheon’s cost plus 10%, the Inventory applicable to the Product which was purchased, produced or maintained by Patheon in contemplation of
filling Firm Orders or in accordance with Section 5.2 prior to notice of termination being given; 

  

	 	(c)	the Client shall satisfy the purchase price payable pursuant to Patheon’s orders with suppliers of Components, provided such orders were made by Patheon in reliance on Firm
Orders; 

  

	 	(d)	Patheon shall return to the Client all unused Active Pharmaceutical Ingredient with shipping, and related expenses, if any, to be borne by the Client, unless termination results
from a breach by Patheon of its obligation hereunder. 

 Any termination or expiration of this Agreement shall not affect any outstanding
obligations or payments due hereunder prior to such termination or expiration, nor shall it prejudice any other remedies that the parties may have under this Agreement. For greater certainty, termination of this Agreement for any reason shall not
affect the obligations and responsibilities of the parties pursuant to Article 9, all of which survive any termination. 
  

 - 17 - 

 ARTICLE 8 - REPRESENTATIONS, WARRANTIES AND COVENANTS 
  

	8.1	Authority. 

 Each party covenants, represents
and warrants that it has the full right and authority to enter into this Agreement, and that it is not aware of any impediment that would inhibit its ability to perform its obligations hereunder. 
  

	8.2	Non-Infringement. 

 The Client covenants,
represents and warrants that: 
  

	 	(a)	the Specifications for the Product are its or its Affiliate’s property and that the Client may lawfully disclose the Specifications to Patheon; 

  

	 	(b)	any Intellectual Property utilized by Patheon in connection with the provision of the Manufacturing Services according to the Specifications (i) is the Client’s or its
Affiliate’s unencumbered property, (ii) may be lawfully used as directed by the Client, and (iii) such use does not infringe and will not infringe any Third Party Rights; 

  

	 	(c)	the provision of the Manufacturing Services by Patheon in respect of any Product pursuant to this Agreement or use or other disposition of any Product by Patheon as may be required
to perform its obligations under this Agreement does not and will not infringe any Third Party Rights; 

  

	 	(d)	there are no actions or other legal proceedings, the subject of which is the infringement of Third Party Rights related to any of the Specifications, or any of the Active
Pharmaceutical Ingredient and the Components, or the sale, use or other disposition of any Product made in accordance with the Specifications; 

  

	 	(e)	the Specifications for the Product conform to all applicable cGMPs, laws and regulations; and 

  

	 	(f)	the Product, if labelled and manufactured in accordance with the Specifications and in compliance with applicable cGMPs (i) may be lawfully sold and distributed in every
jurisdiction in which the Client markets such Products, (ii) will be fit for the purpose intended, and (iii) will be safe for human consumption. 

  

	8.3	Permits. 

 Patheon shall, for the whole term
of this Agreement, obtain and maintain all necessary permits, licenses and registrations required for it to perform its obligations to the Client under this Agreement. The Client shall be solely responsible for obtaining or maintaining, on a timely
basis, any permits or other regulatory approvals in respect of the Product or the Specifications, including, without limitation, all marketing and post-marketing approvals. 
  

 - 18 - 

	8.4	Compliance with Laws. 

 Each party, in
connection with its performance under this Agreement, shall comply with all applicable laws, rules, regulations and orders. 
  

	8.5	No Warranty. 

 PATHEON MAKES NO WARRANTY
OF ANY KIND, EITHER EXPRESSED OR IMPLIED, BY FACT OR LAW, OTHER THAN: (1) THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT; AND (2) ITS OBLIGATION TO DELIVER PRODUCT(S) COMPLYING WITH THE PRODUCT SPECIFICATIONS AND cGMPs. PATHEON MAKES NO
WARRANTY OF MERCHANTABILITY. 
 ARTICLE 9 - REMEDIES AND INDEMNITIES 
  

	9.1	Consequential Damages. 

 Under no
circumstances whatsoever shall either party be liable to the other in contract, tort, negligence, breach of statutory duty or otherwise for any (direct or indirect) loss of profits, of production, of anticipated savings, of business or goodwill or
for any liability, damage, costs or expense of any kind incurred by the other party of an indirect or consequential nature. 
  

	9.2	Limitation of Liability. 

 (a) Active
Pharmaceutical Ingredient. Patheon shall act as the Client’s depositary for the API. As such, Patheon shall be liable for any loss or damage to the API, provided that: such loss or damage (i) occurs while such API are in Patheon’s
possession and control; or (ii) is otherwise due to Patheon’s gross negligence or intentional misconduct. Notwithstanding the foregoing, any liability that results from a breach by Patheon of the Manufacturing Requirements shall be limited
to the API value as listed in Schedule B (the “API Value”) attributable to the relevant API lost or damaged and, in any event, Patheon’s liability for loss or damage to API resulting from a breach by Patheon of the
Manufacturing Requirements shall not exceed the applicable maximum API Value listed in Schedule B (the “Maximum API Value”), in the aggregate, in any Year. 
 (b) Product. Except in circumstances where Patheon has failed to provide the Manufacturing Services in accordance with the Manufacturing
Requirements, Patheon shall not be liable nor have any responsibility for any deficiencies in, or other liabilities associated with, any Product manufactured by it, including, without limitation, the costs and expenses of any recall (collectively,
“Product Claims”). For greater certainty, Patheon shall have no obligation for any Product Claims to the extent such Product Claim (i) is caused by deficiencies with respect to the Specifications, the safety, efficacy or
marketability of the Products or any distribution thereof, (ii) results from a defect in a Component that is not reasonably discoverable using the test methods set forth in the Specifications, (iii) results from a defect in the API or
Components supplied by the Client, (iv) is caused by actions of third 

  

 - 19 - 

 
parties occurring after such Product is shipped by Patheon pursuant to Section 5.4, including, without limitation, any acts or omissions of the
Client’s third party laboratory; (v) is caused by actions or omissions of third party suppliers of Components in which deficiencies or defects were not detectable by Patheon after conducting tests in accordance with the Specifications and
the standard of care generally applied by a prudent manufacturer; (vi) is due to the defects in the artwork and graphics for labels and packaging provided by Client to Patheon; or (vii) is due to any other breach by the Client of its
obligations under this Agreement. 
 (c) Packaging. Patheon shall have no liability hereunder for packaging costs incurred in
connection with defective Products, provided that either (i) the results of the process outlined in paragraph 5.6(b) herein determines that Patheon was not responsible for the deficiencies identified in the Deficiency Notice; or
(ii) Patheon has demonstrated that it has provided the Manufacturing Services in accordance with the Manufacturing Reqirements in the case of a Product recall, as stated in paragraph 6.2(c) herein. 
 (d) Patheon’s maximum liability under this Agreement in any Year for any reason whatsoever, including, without limitation, any liability arising
under Article 6 or Section 5.6 of 9.3 hereof or resulting from a breach of its representations, warranties or other obligations under this Agreement shall not exceed $[ ** ] in the aggregate. 
  

	9.3	Patheon. 

 Subject to Sections 9.1 and 9.2,
Patheon agrees to defend, indemnify and hold the Client, its officers, employees and agents harmless against any and all losses, damages, costs, claims, demands, judgments and liability to, from and in favour of third parties (other than Affiliates)
resulting from, or relating to any claim of personal injury or property damage to the extent that such injury or damage is the result of a breach of Patheon’s representation and warranties contained herein or a failure by Patheon to provide the
Manufacturing Services in accordance with the Manufacturing Requirements except to the extent that any such losses, damages, costs, claims, demands, judgments and liability are due to the negligence or wrongful act(s) of the Client, its officers,
employees or agents or Affiliates. 
 In the event of a claim, the Client shall: (a) promptly notify Patheon of any such claim; (b) use
commercially reasonable efforts to mitigate the effects of such claim; and (c) reasonably cooperate with Patheon in the defence of such claim. 
  

	9.4	Client. 

 Subject to Sections 9.1 and 9.2,
the Client agrees to defend, indemnify and hold Patheon, its officers, employees and agents harmless against any and all losses, damages, costs, claims, demands, judgments and liability to, from and in favour of third parties (other than Affiliates)
resulting from, or relating to any claim of infringement or alleged infringement of any Third Party Rights in respect of the Product, and any claim of personal injury or property damage to the extent that such injury or damage is the result of a
breach any of the Client’s representation and warranties contained herein, or of deficiencies with respect to the Specifications, the safety or efficacy of the Products except to the extent that any such losses, damages, costs, claims, demands,
judgments and liability are due to the negligence or wrongful act(s) of Patheon, its officers, employees or agents. 
  

 - 20 - 

 In the event of a claim, Patheon shall: (a) promptly notify the Client of any such claims; (b) use commercially
reasonable efforts to mitigate the effects of such claim; and (c) reasonably cooperate with the Client in the defence of such claim. 
 ARTICLE 10 - CONFIDENTIALITY 
  

	10.1	Confidentiality. 

 The parties agree that
they are governed by the provisions of the Confidentiality Agreement, which agreement remains in effect in accordance with its terms; provided, however, that in the event the Confidentiality Agreement expires or is terminated prior to the expiration
or termination of this Agreement, the terms of the Confidentiality Agreement shall continue to govern the parties’ obligations of confidentiality with respect to any confidential or proprietary information disclosed by the parties hereunder,
for the term of this Agreement, as though such agreement remained in full force and effect. 
 ARTICLE 11 - DISPUTE RESOLUTION

  

	11.1	Commercial Disputes. 

 In the event of any
dispute arising out of or in connection with this Agreement (other than a dispute determined in accordance with Section 5.6(b) or a Technical Dispute), the parties shall first try to solve it amicably. In this regard, any party may send a
notice of dispute to the other, and each party shall appoint, within ten (10) Business Days from receipt of such notice of dispute, a single representative having full power and authority to solve the dispute. The representatives so designated
shall meet as necessary in order to solve such dispute. If these representatives fail to solve the matter within one month from their appointment, or if a party fails to appoint a representative within the ten (10) Business Day period set forth
above, such dispute shall immediately be referred to the Chief Operating Officer or Executive Vice President, Operations (or such other officer as they may designate) of each party who will meet and discuss as necessary in order to try to solve the
dispute amicably. Should the parties fail to reach a resolution under this Section 11.1, their dispute will be referred to a court of competent jurisdiction in accordance with Section 12.13. 
  

	11.2	Technical Dispute Resolution. 

 In the event
of a dispute (other than disputes in relation to the matters set out in Sections 5.6(b) and 11.1) between the parties that is exclusively related to technical aspects of the manufacturing, packaging, labelling, quality control testing, handling,
storage or other activities under this Agreement (a “Technical Dispute”), the parties shall make all reasonable efforts to resolve the dispute by amicable negotiations. In this regard, senior representatives of each party shall, as
soon as practicable and in any event no later than ten (10) Business Days after a written request from either party to the other, meet in good faith to resolve any Technical 

  

 - 21 - 

 
Dispute. If, despite such meeting, the parties are unable to resolve a Technical Dispute within a reasonable time, and in any event within thirty
(30) Business Days of such written request, the Technical Dispute shall, at the request of either party, be referred for determination to an expert in accordance with the provisions of Schedule C. In the event that the parties cannot agree
whether a dispute is a Technical Dispute, Section 11.1 shall prevail. For greater certainty, the parties agree that the release of the Product for sale or distribution pursuant to the applicable marketing approval for such Product shall not by
itself indicate compliance by Patheon with its obligations in respect of the Manufacturing Services and further that nothing in this Agreement (including Schedule D) shall remove or limit the authority of the relevant qualified person (as specified
by the Quality Agreement) to determine whether the Product is to be released for sale or distribution. 
 ARTICLE 12 - MISCELLANEOUS 

  

	12.1	Intellectual Property. 

 The Client and
Patheon hereby acknowledge that neither party has, nor shall it acquire, any interest in any of the other party’s Intellectual Property unless otherwise expressly agreed to in writing. Each party agrees not to use any Intellectual Property of
the other party, except as specifically authorized by the other party or as required for the performance of its obligations under this Agreement. 
  

	12.2	Insurance. 

 Each party shall maintain
commercial general liability insurance, including blanket contractual liability insurance covering the obligations of that party under this Agreement through the term of this Agreement, which insurance shall afford limits of not less than $[ ** ]
for each occurrence (and in the aggregate only with respect to personal injury liability), products liability and property damage liability. If requested each party will provide the other with a certificate of insurance evidencing the above and
showing the name of the issuing company, the policy number, the effective date, the expiration date and the limits of liability. The insurance certificate shall further provide for a minimum of thirty days’ written notice to the insured of a
cancellation of, or material change in, the insurance. 
  

	12.3	Independent Contractors. 

 The parties are
independent contractors and this Agreement shall not be construed to create between Patheon and the Client any other relationship such as, by way of example only, that of employer-employee, principal agent, joint-venturer, co-partners or any similar
relationship, the existence of which is expressly denied by the parties hereto. 
  

 - 22 - 

	12.4	No Waiver. 

 Either party’s failure to
require the other party to comply with any provision of this Agreement shall not be deemed a waiver of such provision or any other provision of this Agreement. 
  

	12.5	Assignment. 

 Patheon may not assign this
Agreement or any of its rights or obligations hereunder except with the written consent of the Client, such consent not to be unreasonably withheld. For greater certainty, Patheon may arrange for subcontractors to perform specific services arising
under this Agreement provided that Patheon remains responsible to the Client under this Agreement. Subject to Section 7.2(d), the Client may assign this Agreement or any of its rights or obligations hereunder without approval from Patheon;
provided, however, that the Client shall give prior written notice of any assignment to Patheon and that any assignee shall covenant in writing with Patheon to be bound by the terms of this Agreement. Notwithstanding the foregoing provisions of this
Section 12.5 and of Section 7.2(d), either party may assign this Agreement to any of its Affiliates or to a successor to or purchaser of all or substantially all of its business, provided that such assignee executes an agreement with the
non-assigning party hereto whereby it agrees to be bound hereunder. 
  

	12.6	Force Majeure. 

 Neither party shall be
liable for the failure to perform its obligations under this Agreement if such failure is occasioned by a cause or contingency beyond such party’s reasonable control, including, but not limited to, riots, wars, acts of terrorism, fires, floods,
storms, interruption of or delay in transportation, defective equipment, lack of or inability to obtain fuel, power or components or compliance with any order or regulation of any government entity acting within colour of right (a “Force
Majeure Event”). A party claiming a right to excused performance under this Section 12.6 shall immediately notify the other party in writing of the extent of its inability to perform, which notice shall specify the occurrence beyond
its reasonable control that prevents such performance. Neither party shall be entitled to rely on a Force Majeure Event to relieve it from an obligation to pay money (including any interest for delayed payment) that would otherwise be due and
payable under this Agreement. 
  

	12.7	Additional Product. 

 Additional products may
be added to this Agreement and such additional products shall be governed by the general conditions hereof with any special terms (including, without limitation, price) governed by an addendum hereto. 
  

	12.8	Notices. 

 All communications and other
notices under this Agreement shall be in writing and shall be considered as duly given if delivered personally or sent by registered letter with return receipt or transmitted by fax, confirmed by registered letter sent within two (2) working
days following the date of the fax to the parties at the following addresses (or at any other address which the parties shall have indicated giving notice thereof in the ways set forth above): 
  

 - 23 - 

 (a) as to the Client, to: 
 AXCAN PHARMA INC. 
 597, boulevard Laurier 
 Mont-St-Hilaire (Québec) 
 J3H 6C4 
 Attention: General Counsel 
 Tel. No.: (450) 467-5138 
 Fax No.: (450) 464-9979 
 (b) as to Patheon, to:  
 PATHEON
INC. 
 7070 Mississauga Road, Suite 350 
 Mississauga, Ontario L5N 7J8 
 Canada 
 Attention: General Counsel 
 Tel. No.:
905-821-4001 
 Fax No.: 905-812-6613 
 All the
communications and other notices under this Agreement which have been delivered in person or which have been transmitted by fax and confirmed by registered letter sent within 2 (two) working days following the date of the fax, shall be considered as
received by the addressee respectively upon the date of delivery in person or on the third working day subsequent to that of the date of the fax. 
  

	12.9	Severability. 

 If any provision of this
Agreement is determined by a court of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such determination shall not impair or affect the validity, legality or enforceability of the remaining provisions hereof, and each
provision is hereby declared to be separate, severable and distinct. 
  

	12.10	Entire Agreement. 

 This Agreement, together
with the Quality Agreement and the Confidentiality Agreement, constitutes the full, complete, final and integrated agreement between the parties hereto relating to the subject matter hereof and supersedes all previous written or oral negotiations,
commitments, agreements, transactions or understandings with respect to the subject matter hereof. Any modification, amendment or supplement to this Agreement must be in writing and signed by authorized representatives of both parties. In case of
conflict, the prevailing order of documents shall be this Agreement, the Quality Agreement and the Confidentiality Agreement. 
  

 - 24 - 

	12.11	No Third Party Benefit or Right. 

 For
greater certainty, nothing in this Agreement shall confer or be construed as conferring on any third party any benefit or the right to enforce any express or implied term of this Agreement. 
  

	12.12	Execution in Counterparts. 

 This Agreement
may be executed in two counterparts, by original or facsimile signature, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  

	12.13	Governing Law. 

 This Agreement shall be
construed and enforced in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein. The parties expressly agree that the UN Convention on Contracts for the International Sale of Goods shall not apply to
this Agreement. 
 IN WITNESS WHEREOF, the duly authorized representatives of the parties have executed this Agreement as of the date
first written above. 
  

							
	PATHEON INC.	  	AXCAN PHARMA INC.
				
	by	 	 /s/ Clive V. Bennett
	  	by	 	 /s/ Jean-François Hébert

		 	Clive V. Bennett	  		 	Jean-François Hébert
		 	President, Patheon N.A.	  		 	Vice President,
		 		  		 	Manufacturing Operations and Technical Services
				
		 		  	by	 	 /s/ Richard Tarte

		 		  		 	Richard Tarte
		 		  		 	Vice President,
		 		  		 	Corporate Development and General Counsel

  

 - 25 - 

 SCHEDULE A - 
 PRODUCT, MINIMUM RUN QUANTITY AND FEES 
  

													
	 Product
	  	 Description
	  	 Market
	  	 Minimum 
Run Quantity
	  	 Estimated
Annual Volume
	  	 Target Yield
	  	 Unit Price

	 [ ** ]
	  	URSO 250MG FCT 100’s	  	US	  	[ ** ] btls	  	[ ** ] btls	  	[ ** ] %	  	[ ** ] USD
	 [ ** ]
	  	URSO 250MG FCT 100’s	  	CDA	  	[ ** ] btls	  	[ ** ] btls	  	[ ** ] %	  	[ ** ] CDN
	 [ ** ]
	  	URSO 250MG FCT 500’s	  	US	  	[ ** ] btls	  	[ ** ] btls	  	[ ** ] %	  	[ ** ] USD
	 [ ** ]
	  	URSO 250MG FCT 2 x 4’s	  	US	  	[ ** ] units	  	[ ** ] btls	  	[ ** ] %	  	[ ** ] USD
	 [ ** ]
	  	URSO 250MG FCT 5 x 4’s	  	CDA	  	[ ** ] units	  	[ ** ] units	  	[ ** ] %	  	[ ** ] CDN
	 [ ** ]
	  	URSO 500MG FCT 100’s	  	CDA	  	[ ** ] btls	  	[ ** ] btls	  	[ ** ] %	  	[ ** ] CDN
	 [ ** ]
	  	VIOKASE POWDER 4OZ	  	CDA	  	[ ** ] btls	  	[ ** ] btls	  	[ ** ] %	  	[ ** ]1 CDN
	 [ ** ]
	  	VIOKASE POWDER 8OZ	  	US	  	[ ** ] btls	  	[ ** ] btls	  	[ ** ] %	  	[ ** ]2 USD
	 [ ** ]
	  	VIOKASE 8000 U CT 500’s	  	US	  	[ ** ] btls	  	[ ** ] btls	  	[ ** ] %	  	[ ** ]3 USD
	 [ ** ]
	  	VIOKASE 16000 U CT 500’s	  	US	  	[ ** ] btls	  	[ ** ] btls	  	[ ** ] %	  	[ ** ] USD

 1
 [ ** ] 
 2 [ ** ] 
 3 [ ** ] 

 SCHEDULE B 
 ACTIVE PHARMACEUTICAL INGREDIENT & VALUE 
  

									
	 Product
	 	 Active Pharmaceutical
Ingredient
	 	 Supplier
	 	 API Value
	 	 Maximum
 API Value

	 URSO® 250 mg FCT
 URSO® 500 mg FCT
	 	Ursodiol	 	Axcan Pharma Inc.	 	[ ** ] per Kg	 	$[ ** ] per year
					
	 VIOKASE® 8,000 U CT
 VIOKASE® 16,000 U CT
	 	 Pancreatic Enzyme
 Concentrate (PEC)
	 	Axcan Pharma Inc.	 	[ ** ] per Kg	 	$[ ** ] per year
					
	 VIOKASE POWDER®
	 	 Pancreatic Enzyme
 Concentrate (PEC)
	 	Axcan Pharma Inc.	 	[ ** ] per Kg	 	$[ ** ] per year

 The API Value information provided above is provided as of October 1, 2003. Any modifications
to such information shall be agreed in writing by the parties. 

 SCHEDULE C 
 TECHNICAL DISPUTE RESOLUTION 
 Technical Disputes which cannot be resolved by negotiation as provided in
Section 11.2 shall be resolved in the following matter: 
 1. Appointment of Expert. Within 10 Business Days after a party requests
pursuant to Section 11.2 that an expert be appointed to resolve a Technical Dispute, the parties shall jointly appoint a mutually acceptable expert with experience and expertise in the subject matter of the dispute. If the parties are unable to
so agree within such 10 Business Day period, or in the event of disclosure of a conflict by an expert pursuant to paragraph 2 hereof which results in the parties not confirming the appointment of such expert, then an expert (willing to act in that
capacity hereunder) shall be appointed by an experienced arbitrator on the roster of ADR Chambers who shall be a retired judge of the Ontario Superior Court of Justice. 
 2. Conflicts of Interest. Any person appointed as an expert shall be entitled to act and continue to act as such notwithstanding that at the time of his appointment or at any time before he gives his
determination, he has or may have some interest or duty which conflicts or may conflict with his appointment provided that before accepting such appointment (or as soon as practicable after he becomes aware of the conflict or potential conflict) he
fully discloses any such interest or duty and the parties shall after such disclosure have confirmed his appointment. 
 3. Not Arbitrator. No
expert shall be deemed to be an arbitrator and the provisions of the Arbitration Act, 1991 (Ontario) or of any other applicable statute (foreign or domestic) and the law relating to arbitration shall not apply to any such expert or the
expert’s determination or the procedure by which the expert reaches his determination to be made pursuant to this Schedule C. 
 4. Procedure.
Where an expert is appointed: 
  

	 	(a)	Timing. The expert shall be so appointed on condition that (i) he promptly fixes a reasonable time and place for receiving representations, submissions or information
from the parties and that he issues such authorizations to the parties and any relevant third party for the proper conduct of his determination and any hearing and (ii) he renders his decision (with full reasons) within 15 Business Days (or
such other date as the parties and the expert may agree) after receipt of all information requested by him pursuant to paragraph 4(b) hereof. 

  

	 	(b)	Disclosure of Evidence. The parties undertake one to the other to provide to any expert all such evidence and information within their respective possession or control as the
expert may reasonably consider necessary for determining the matter before him which they shall disclose promptly and in any event within five Business Days of a written request from the relevant expert to do so. 

	 	(c)	Advisors. Each party may appoint such counsel, consultants and advisors as it feels appropriate to assist the expert in his determination and so as to present their
respective cases so that at all times the parties shall co-operate and seek to narrow and limit the issues to be determined. 

  

	 	(d)	Appointment of New Expert. If within the time specified in paragraph 4(a) above the expert shall not have rendered a decision in accordance with his appointment, a new expert
may (at the request of either party) be appointed and the appointment of the existing expert shall thereupon cease for the purposes of determining the matter at issue between the parties save that if the existing expert renders his decision with
full reasons prior to the appointment of the new expert, then such a decision shall have effect and the proposed appointment of the new expert shall be withdrawn. 

  

	 	(e)	Final and Binding. The determination of the expert shall, save in the event of fraud or manifest error, be final and binding upon the parties. 

  

	 	(f)	Costs. Each party shall bear its own costs in connection with any matter referred to an expert hereunder and, in the absence of express provision in the Agreement to the
contrary, the costs and expenses of the expert shall be shared equally by the parties. 

 For greater certainty, the parties agree that the
release of the Products for sale or distribution pursuant to the applicable marketing approval for such Products shall not by itself indicate compliance by Patheon with its obligations in respect of the Manufacturing Services and further that
nothing in this Agreement (including this Schedule C) shall remove or limit the authority of the relevant qualified person (as specified by the Quality Agreement) to determine whether the Products are to be released for sale or distribution.

 SCHEDULE D 
 QUALITY AGREEMENT 
 See Quality Agreement between the parties dated October 1, 2003. 

 SCHEDULE E 
 BATCH NUMBERING AND EXPIRATION DATES 
 Products manufactured at Patheon will bear lot numbers as described in
Patheon SOP MMG001 and will have expiry dates as described in Patheon SOP MCT154. 

 SCHEDULE F 
 FINISHED PRODUCT SPECIFICATIONS 
 The Finished Product Specifications for the Products have been mutually
agreed upon and delivered to Patheon. 

 SCHEDULE G 
 LOGISTICS ROUTING GUIDE 
 URSO® TABLETS, VIOKASE® TABLETS and VIOKASE® POWDER  
 [ ** ] 

 SCHEDULE H* 
 COMPONENT LIABILITY 
 [ ** ]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}]]